Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

At ~~July~~October 28, 2022, there were ~~33,164,721~~33,198,067 issued and outstanding shares of Common Stock of the registrant.

Derivative Financial Instruments

The Company is exposed to various market risks including, but not limited to, changes in foreign currency exchange rates, changes in interest rates and price fluctuations of certain material commodities such as copper. Market risks for changes in interest rates relate primarily to its debt obligations under the Second Amended and Restated Credit Agreement. Foreign currency exchange risks are attributable to sales to foreign customers and purchases from foreign suppliers not denominated in a location’s functional currency, foreign plant operations, intercompany indebtedness, acquisitions denominated in foreign currencies, intercompany investments and include exposures to the Euro, Mexican Peso, Canadian Dollar, Hungarian Forint, North Macedonian Denar, Ukrainian Hryvnia, Japanese Yen, Chinese Renminbi, Korean Won and Vietnamese Dong.

The Company regularly enters into derivative contracts with the objective of managing its financial and operational exposure arising from these risks by offsetting gains and losses on the underlying exposures with gains and losses on the financial instruments used to hedge them. The decision of whether and when to execute derivative financial instruments, along with the duration of the instrument, may vary from period to period depending on market conditions, the relative costs of the instruments and capacity to hedge. The duration is linked to the timing of the underlying exposure, with the connection between the two being regularly monitored. The Company does not enter into derivative financial instruments for speculative or trading purposes. Some derivative contracts do not qualify for hedge accounting; for other derivative contracts, we elect to not apply hedge accounting.

The Company’s designated hedging relationships are formally documented at the inception of the hedge, and hedges must be highly effective in offsetting changes to future cash flows on hedged transactions both at the inception of a hedge and on an ongoing basis to be designated for hedge accounting treatment. For derivative contracts which can be classified as a cash flow hedge, the effective portion of the change in the fair value of the derivative is recorded to Accumulated other comprehensive loss in the consolidated condensed balance sheets. When the underlying hedge transaction is realized, the gain or loss included in Accumulated other comprehensive loss is recorded in earnings in the consolidated condensed statements of income on the same line as the gain or loss on the hedged item attributable to the hedged risk. The Company records the ineffective portion of designated foreign currency and copper commodity hedging instruments, if any, to cost of sales in the consolidated condensed statements of income. Cash flows associated with derivatives are reported in net cash ~~(used in)~~ provided by operating activities in the Company’s consolidated condensed statements of cash flows.

The Company uses an income approach to value derivative instruments, analyzing quoted market prices to calculate the forward values and then discounting such forward values to the present value using benchmark rates at commonly quoted intervals for the instrument’s full term.

~~During~~In the ~~three months ended June 30,~~second quarter of 2022, the Company entered into a floating-to-fixed interest rate swap agreement with a notional amount of $100,000. This interest rate swap is an undesignated hedge of the Company’s exposure to interest payment fluctuations on a portion of the ~~expected~~ Credit Facility borrowings ~~to be~~that were drawn for the acquisitions of Alfmeier and Dacheng. ~~See Note 15, “Subsequent Events,” for information about the Company’s acquisition activities.~~ The periodic changes in fair value is recognized in Interest expense, net.

~~During~~In the ~~three months ended June 30,~~second and third quarter of 2022, the Company entered into forward contracts with a notional amount of $128,319 to hedge the foreign currency risk associated with the forecasted purchase of Alfmeier. These ~~forward~~ contracts ~~are not designated as hedging instruments. The periodic changes~~matured and were settled in ~~fair value is~~the third quarter of 2022. During the three and nine months ended September 30, 2022 the Company recognized expense of $4,288 and $3,806, respectively, in Foreign currency (loss) gain ~~(loss).~~within the consolidated condensed income statement.

Information related to the recurring fair value measurement of derivative instruments in our consolidated condensed balance sheet as of ~~June~~September 30, 2022 is as follows:


				Asset Derivatives			Liability Derivatives								Asset Derivatives			Liability Derivatives
	Fair Value Hierarchy	Notional Amount		Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value		Net Asset/ (Liabilities)		Fair Value Hierarchy	Notional Amount		Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value		Net Asset/ (Liabilities)
Derivatives Designated as Cash Flow Hedges
Foreign currency derivatives	Level 2	$	14,075	Other current assets	$	588	Other current liabilities	$	—	$	588	Level 2	$	47,040	Other current assets	$	2,216	Other current liabilities	$	—	$	2,216
Derivatives Not Designated as Hedging Instruments
Foreign currency derivatives	Level 2	$	128,319	Other current assets	$	1,403	Other current liabilities	$	921	$	482
Interest rate contracts	Level 2	$	100,000	Other current assets	$	—	Other current liabilities	$	693	$	693	Level 2	$	100,000	Other current assets	$	2,498	Other current liabilities	$	—	$	2,498

Information related to the recurring fair value measurement of derivative instruments in our consolidated condensed balance sheet as of December 31, 2021 is as follows:


				Asset Derivatives			Liability Derivatives
	Fair Value Hierarchy	Notional Amount		Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value		Net Asset/ (Liabilities)
Derivatives Designated as Cash Flow Hedges
Foreign currency derivatives	Level 2	$	13,974	Other current assets	$	294	Other current liabilities	$	—	$	294
Commodity hedges	Level 2	$	309	Other current assets	$	6	Other current liabilities	$	—	$	6

Information relating to the effect of derivative instruments on our consolidated condensed statements of income and the consolidated condensed statements of comprehensive income is as follows:


		Three Months Ended June 30,						Six Months Ended June 30,							Three Months Ended September 30,						Nine Months Ended September 30,
	Location	2022			2021			2022			2021			Location	2022			2021			2022			2021
Derivatives Designated as Cash Flow Hedges
Foreign currency derivatives	Cost of sales – income	$	333		$	529		$	486		$	1,007		Cost of sales – income	$	321		$	448		$	807		$	1,455
	Other comprehensive (loss) income		(316	)		(62	)		294			(729	)	Other comprehensive (loss) income		1,627			(606	)		1,921			(1,335	)
Total foreign currency derivatives		$	17		$	467		$	780		$	278			$	1,948		$	(158	)	$	2,728		$	120

Commodity derivatives	Cost of sales – income	$	—		$	—		$	19		$	—		Cost of sales – income	$	—		$	2		$	19		$	2
	Other comprehensive loss		—			—			(6	)		—		Other comprehensive loss		—			(44	)		(6	)		(44	)
Total commodity derivatives		$	—		$	—		$	13		$	—			$	—		$	(42	)	$	13		$	(42	)

Derivatives Not Designated as Hedging Instruments
Foreign currency derivatives	Foreign currency gain (loss)	$	482		$	—		$	482		$	—		Foreign currency (loss) gain	$	(4,288	)	$	—		$	(3,806	)	$	—
Total foreign currency derivatives		$	482		$	—		$	482		$	—			$	(4,288	)	$	—		$	(3,806	)	$	—

Interest rate contracts	Interest expense, net	$	(693	)	$	—		$	(693	)	$	—		Interest income (expense), net	$	3,191		$	—		$	2,498		$	—
Total interest rate derivatives		$	(693	)	$	—		$	(693	)	$	—			$	3,191		$	—		$	2,498		$	—

Accounts Receivable Factoring

The Company is party to a receivable factoring ~~agreement~~agreements with ~~HSBC Bank USA, National Association. Under the receivable factoring agreement,~~unrelated third parties under which we can sell receivables for certain ~~of our North America~~ account debtors, ~~up to $41,300~~, on a revolving basis, subject to outstanding balances and concentration limits. The receivable factoring agreements are transferred in their entirety to the acquiring entities and are accounted for as a sale. Some of the agreements, including those assumed through the acquisition of Alfmeier, have deferred purchase price arrangements. As of ~~June~~September 30, 2022, there were $020,221 outstanding receivables transferred under the receivable factoring ~~agreement~~agreements and our availability under the receivables factoring ~~agreement~~agreements was $~~32,431~~37,976.

Note 1011 – Fair Value Measurements

Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Fair value measurements are based on one or more of the following three valuation techniques:

Market: This approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities.

Income: This approach uses valuation techniques to convert future amounts to a single present value amount based on current market expectations.

Cost: This approach is based on the amount that would be required to replace the service capacity of an asset (replacement cost).

The Company uses the following fair value hierarchy to measure fair value into three broad levels, which are described below:

Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2: Inputs, other than quoted market prices included in Level 1, that are observable either directly or indirectly for the asset or liability.

Level 3: Unobservable inputs that are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

Items Measured at Fair Value on a Recurring Basis

Except for derivative instruments (see Note 9)10) and pension plan assets, the Company had 0no material financial assets and liabilities that were carried at fair value at ~~June~~September 30, 2022 and December 31, 2021. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and also considers counterparty credit risk in its assessment of fair value.

Items Measured at Fair Value on a Nonrecurring Basis

The Company measures certain assets and liabilities at fair value on a non-recurring basis. As these nonrecurring fair value measurements are generally determined using unobservable inputs, these fair value measurements are classified within Level 3 of the fair value hierarchy. ~~As of June 30, 2022 and December 31, 2021, there were~~ 0 ~~significant assets or liabilities measured at~~The Company utilized a third-party to assist in the Level 3 fair value estimates of other intangible assets for recent acquisitions (see Note 3). The estimated fair values of these assets were based on ~~a non-recurring basis.~~third-party valuations and management’s estimates, generally utilizing income and market approaches.

Items Not Carried at Fair Value

The Company uses an income valuation technique to measure the fair values of its debt instruments by converting amounts of future cash flows to a single present value amount using rates based on current market expectations (Level 2 inputs). As of ~~June~~September 30, 2022, and December 31, 2021, the carrying values of the indebtedness under the Company’s Second Amended and Restated Credit Agreement were not materially different than the estimated fair values because the interest rates on variable rate debt approximated rates currently available to the Company (see Note 6)7). ~~Discount rates used to measure the fair value of Gentherm’s DEG Vietnam Loan are based on quoted swap rates. As of June 30, 2022, the carrying value of the DEG Vietnam Loan was $2,500~~ ~~as compared to an estimated fair value of $2,490. As of December 31, 2021, the carrying value of the DEG Vietnam Loan was $3,750~~ ~~as compared to an estimated fair value of $3,778~~.

Note 1112 – Equity

In December 2020, the Board of Directors of Gentherm Incorporated (“Board of Directors”) authorized a stock repurchase program (the “2020 Stock Repurchase Program”) to commence upon expiration of the prior stock repurchase program on December 15, 2020. Under the 2020 Stock Repurchase Program, the Company is authorized to repurchase up to $150,000 of its issued and outstanding common stock over a three-year period, expiring December 15, 2023.

Repurchases may be made, from time to time, in amounts and at prices the Company deems appropriate, subject to market conditions, applicable legal requirements, debt covenants and other considerations. Any such repurchases may be executed using open market purchases, privately negotiated agreements or other transactions. Repurchases may be funded from cash on hand, available borrowings or proceeds from potential debt or other capital markets sources. The Company did 0not make any repurchases under the 2020 Stock Repurchase Program during the ~~six~~three and nine months ended ~~June~~September 30, 2022, or ~~June~~September 30, 2021. The 2020 Stock Repurchase Program had $130,000 repurchase authorization remaining as of ~~June~~September 30, 2022.

Note 1213 – Reclassifications Out of Accumulated Other Comprehensive Loss

Reclassification adjustments and other activities impacting Accumulated other comprehensive loss during the three and ~~six~~nine months ended ~~June~~September 30, 2022 and 2021 were as follows:


	Defined Benefit Pension Plans			Foreign Currency Translation Adjustments			Foreign Currency Hedge Derivatives				Commodity Hedge Derivatives			Total			Defined Benefit Pension Plans			Foreign Currency Translation Adjustments			Foreign Currency Hedge Derivatives				Commodity Hedge Derivatives			Total
Balance at March 31, 2022	$	(2,864	)	$	(43,482	)	$	618			$	—		$	(45,728	)
Balance at June 30, 2022																	$	(2,837	)	$	(66,182	)	$	371			$	—		$	(68,648	)
Other comprehensive (loss) income before reclassifications		—			(22,458	)		17				—			(22,441	)		—			(28,411	)		1,948				—			(26,463	)
Income tax effect of other comprehensive (loss) income before reclassifications		—			(242	)		(4	)			—			(246	)		—			(271	)		(423	)			—			(694	)
Amounts reclassified from accumulated other comprehensive loss into net income		35			—			(333	)	a		—	a		(298	)		6			—			(321	)	a		—	a		(315	)
Income taxes reclassified into net income		(8	)		—			73				—			65			—			—			69				—			69
Net current period other comprehensive income (loss)		27			(22,700	)		(247	)			—			(22,920	)		6			(28,682	)		1,273				—			(27,403	)
Balance at June 30, 2022	$	(2,837	)	$	(66,182	)	$	371			$	—		$	(68,648	)
Balance at September 30, 2022																	$	(2,831	)	$	(94,864	)	$	1,644			$	—		$	(96,051	)

(a)

The amounts reclassified from accumulated other comprehensive loss were included in cost of sales.

Defined
Benefit
Pension
Plans

Foreign
Currency
Translation
Adjustments

Foreign
Currency
Hedge
Derivatives

Commodity Hedge
Derivatives

Total

Balance at March 31, 2021

$
(3,451
)

$
(25,789
)

$
584

$
—

$
(28,656
)
Other comprehensive income before reclassifications

—

4,531

364

—

4,895

Income tax effect of other comprehensive income before reclassifications

—

(3
)

(79
)

—

(82
)
Amounts reclassified from accumulated other comprehensive loss into net income

—

—

(426
)
a

—

a

(426
)
Income taxes reclassified into net income

—

—

93

—

93

Net current period other comprehensive income (loss)

—

4,528

(48
)

—

4,480

Balance at June 30, 2021

$
(3,451
)

$
(21,261
)

$
536

$
—

$
(24,176
)


	Defined Benefit Pension Plans			Foreign Currency Translation Adjustments			Foreign Currency Hedge Derivatives				Commodity Hedge Derivatives				Total
Balance at June 30, 2021	$	(3,451	)	$	(21,261	)	$	536			$	—			$	(24,176	)
Other comprehensive loss before reclassifications		—			(7,267	)		(158	)			(42	)			(7,467	)
Income tax effect of other comprehensive loss before reclassifications		—			(165	)		35				9				(121	)
Amounts reclassified from accumulated other comprehensive loss into net income		—			—			(448	)	a		(2	)	a		(450	)
Income taxes reclassified into net income		—			—			97				—				97
Net current period other comprehensive loss		—			(7,432	)		(474	)			(35	)			(7,941	)
Balance at September 30, 2021	$	(3,451	)	$	(28,693	)	$	62			$	(35	)		$	(32,117	)

(a)

The amounts reclassified from accumulated other comprehensive loss were included in cost of sales.


	Defined Benefit Pension Plans			Foreign Currency Translation Adjustments			Foreign Currency Hedge Derivatives				Commodity Hedge Derivatives				Total			Defined Benefit Pension Plans			Foreign Currency Translation Adjustments			Foreign Currency Hedge Derivatives				Commodity Hedge Derivatives				Total
Balance at December 31, 2021	$	(2,893	)	$	(34,188	)	$	154			$	5			$	(36,922	)	$	(2,893	)	$	(34,188	)	$	154			$	5			$	(36,922	)
Other comprehensive (loss) income before reclassifications		—			(31,612	)		780				13				(30,819	)		—			(60,023	)		2,728				13				(57,282	)
Income tax effect of other comprehensive loss before reclassifications		—			(382	)		(183	)			(3	)			(568	)
Income tax effect of other comprehensive (loss) income before reclassifications																			—			(653	)		(606	)			(3	)			(1,262	)
Amounts reclassified from accumulated other comprehensive loss into net income		70			—			(486	)	a		(19	)	a		(435	)		76			—			(807	)	a		(19	)	a		(750	)
Income taxes reclassified into net income		(14	)		—			106				4				96			(14	)		—			175				4				165
Net current period other comprehensive income (loss)		56			(31,994	)		217				(5	)			(31,726	)		62			(60,676	)		1,490				(5	)			(59,129	)
Balance at June 30, 2022	$	(2,837	)	$	(66,182	)	$	371			$	—			$	(68,648	)
Balance at September 30, 2022																		$	(2,831	)	$	(94,864	)	$	1,644			$	—			$	(96,051	)

(a)

The amounts reclassified from accumulated other comprehensive loss were included in cost of sales.

1821


	Defined Benefit Pension Plans			Foreign Currency Translation Adjustments			Foreign Currency Hedge Derivatives				Commodity Hedge Derivatives			Total			Defined Benefit Pension Plans			Foreign Currency Translation Adjustments			Foreign Currency Hedge Derivatives				Commodity Hedge Derivatives				Total
Balance at December 31, 2020	$	(3,451	)	$	(12,637	)	$	1,106			$	—		$	(14,982	)	$	(3,451	)	$	(12,637	)	$	1,106			$	—			$	(14,982	)
Other comprehensive (loss) income before reclassifications		—			(8,341	)		206				—			(8,135	)		—			(15,608	)		120				(42	)			(15,530	)
Income tax effect of other comprehensive (loss) income before reclassifications		—			(283	)		(45	)			—			(328	)		—			(448	)		(26	)			9				(465	)
Amounts reclassified from accumulated other comprehensive loss into net income		—			—			(935	)	a		—	a		(935	)		—			—			(1,455	)	a		(2	)	a		(1,457	)
Income taxes reclassified into net income		—			—			204				—			204			—			—			317				—				317
Net current period other comprehensive loss		—			(8,624	)		(570	)			—			(9,194	)		—			(16,056	)		(1,044	)			(35	)			(17,135	)
Balance at June 30, 2021	$	(3,451	)	$	(21,261	)	$	536			$	—		$	(24,176	)
Balance at September 30, 2021																	$	(3,451	)	$	(28,693	)	$	62			$	(35	)		$	(32,117	)

(a)

The amounts reclassified from accumulated other comprehensive loss were included in cost of sales.

The Company expects all of the existing gains and losses related to foreign currency derivatives reported in Accumulated other comprehensive loss as of ~~June~~September 30, 2022 to be reclassified into earnings during the next twelve months. See Note 910 for additional information about derivative financial instruments and the effects from reclassification to net income.

Note 1314 – Income Taxes

At the end of each interim period, the Company makes its best estimate of the annual expected effective income tax rate and applies that rate to its ordinary year-to-date earnings or loss. The income tax provision or benefit related to unusual or infrequent items, if applicable, that will be separately reported or reported net of their related tax effects are individually computed and recognized in the interim period in which those items occur. In addition, the effect of changes in enacted tax laws or rates, tax status, judgment on the realizability of a beginning-of-the-year deferred tax asset in future years or income tax contingencies is recognized in the interim period in which the change occurs.

The computation of the annual expected effective income tax rate at each interim period requires certain estimates and assumptions including, but not limited to, the expected pre-tax income (or loss) for the year, projections of the proportion of income (and/or loss) earned and taxed in respective jurisdictions, permanent and temporary differences, and the likelihood of the realizability of deferred tax assets generated in the current year. Jurisdictions with a projected loss for the year for which no tax benefit can be recognized due to a valuation allowance are excluded from the estimated annual effective tax rate. The impact of such an exclusion could result in a higher or lower effective tax rate during a particular quarter, based upon the composition and timing of actual earnings compared to annual projections. The estimates used to compute the provision or benefit for income taxes may change as new events occur, additional information is obtained or as our tax environment changes. To the extent that the expected annual effective income tax rate changes, the effect of the change on prior interim periods is included in the income tax provision in the period in which the change in estimate occurs.

A summary of the provision for income taxes and the corresponding effective tax rate for the three and ~~six~~nine months ended ~~June~~September 30, 2022 and 2021, is shown below:


	Three Months Ended June 30,						Six Months Ended June 30,						Three Months Ended September 30,						Nine Months Ended September 30,
	2022			2021			2022			2021			2022			2021			2022			2021
Income tax expense	$	3,919		$	5,748		$	8,214		$	13,313		$	5,784		$	4,646		$	13,998		$	17,959
Earnings before income tax	$	10,991		$	30,539		$	27,033		$	71,013		$	15,611		$	20,332		$	42,644		$	91,345
Effective tax rate		35.7	%		18.8	%		30.4	%		18.7	%		37.1	%		22.9	%		32.8	%		19.7	%

Income tax expense was $~~3,919~~5,784 for the three months ended ~~June~~September 30, 2022 on earnings before income tax of $~~10,991~~15,611, representing an effective tax rate of ~~35.7~~37.1%. The effective tax rate differed from the U.S. Federal statutory rate of 21.0% primarily due to the impact of income taxes on foreign earnings taxed at rates varying from the U.S. statutory rate, the unfavorable impact of the global intangible low-tax income (“GILTI”), and the quarterly accrual for uncertain tax positions partially offset by the impact of certain favorable tax effects on equity vesting.

1922

Income tax expense was $~~5,748~~4,646 for the three months ended ~~June~~September 30, 2021 on earnings before income tax of $~~30,539~~20,332, representing an effective tax rate of ~~18.8~~22.9%. The effective tax rate differed from the U.S. Federal statutory rate of 2121.0% primarily due to ~~certain favorable~~the unfavorable impact of quarterly accrual for uncertain tax ~~effect on equity vesting~~positions, GILTI, withholding taxes and ~~intercompany transactions in the second quarter of 2021,~~other non-deductible expenses, partially offset by ~~unfavorable~~the impact of ~~GILTI.~~income taxes on foreign earnings taxed at rates varying from the U.S. statutory rate in the third quarter of 2021.

Income tax expense was $~~8,214~~13,998 for the ~~six~~nine months ended ~~June~~September 30, 2022 on earnings before income tax of $~~27,033~~42,644, representing an effective tax rate of ~~30.4~~32.8%. The effective tax rate differed from the U.S. Federal statutory rate of 21% primarily due to the impact of income taxes on foreign earnings taxed at rates varying from the U.S. statutory rate, the unfavorable impact of GILTI, and the quarterly accrual for uncertain tax positions, partially offset by the impact of certain favorable tax effects of equity ~~vesting.~~vesting.

Income tax expense was $~~13,313~~17,959 for the ~~six~~nine months ended ~~June~~September 30, 2021 on earnings before income tax of $~~71,013~~91,345, representing an effective tax rate of ~~18.7~~19.7%. The effective tax rate differed from the U.S. Federal statutory rate of 21% primarily due to certain favorable tax effect on equity vesting, ~~and~~ intercompany transactions in 2021 and the impact of income taxes on foreign earnings taxed at rates varying from the U.S. statutory rate, partially offset by the unfavorable impact of ~~GILTI.~~uncertain tax positions, GILTI, withholding taxes and other non-deductible expenses.

Note 1415 – Segment Reporting

Segment information is used by management for making strategic operating decisions for the Company. Management evaluates the performance of the Company’s segments based primarily on operating income or loss.

The Company’s reportable segments are as follows:

•

Automotive – this segment represents the design, development, manufacturing and sales of automotive climate comfort systems, automotive cable systems, lumbar and massage comfort solutions, valve system technologies, battery performance solutions, and automotive electronic and software systems.

•

Medical – this segment represents the results from our patient temperature management business within the medical industry.

The Corporate category includes unallocated costs related to our corporate headquarter activities, including selling, general and administrative costs and acquisition transaction costs, which do not meet the requirements for being classified as an operating segment.

The tables below present segment information about the reported product revenues, depreciation and amortization and operating income (loss) of the Company for three and ~~six~~nine months ended ~~June~~September 30, 2022 and 2021.


Three Months Ended June 30,	Automotive		Medical			Corporate			Total
Three Months Ended September 30,											Automotive		Medical			Corporate			Total
2022
Product revenues	$	249,152	$	11,563		$	—		$	260,715	$	322,555	$	10,407		$	—		$	332,962
Depreciation and amortization		8,197		558			305		$	9,060		10,499		1,035			302		$	11,836
Operating income (loss)		24,026		(181	)		(16,110	)	$	7,735		43,067		(2,232	)		(18,014	)	$	22,821
2021
Product revenues	$	255,105	$	10,900		$	—		$	266,005	$	233,028	$	10,356		$	—		$	243,384
Depreciation and amortization		8,892		580			245		$	9,717		8,977		654			228		$	9,859
Operating income (loss)		43,544		113			(11,985	)	$	31,672		33,129		(974	)		(11,451	)	$	20,704


Six Months Ended June 30,	Automotive		Medical			Corporate			Total
Nine Months Ended September 30,											Automotive		Medical			Corporate			Total
2022
Product revenues	$	507,016	$	21,356		$	—		$	528,372	$	829,570	$	31,764		$	—		$	861,334
Depreciation and amortization		16,863		1,162			610		$	18,635		27,333		2,224			913		$	30,470
Operating income (loss)		55,301		(1,032	)		(32,344	)	$	21,925		98,367		(3,264	)		(50,356	)	$	44,747
2021
Product revenues	$	534,475	$	20,065		$	—		$	554,540	$	767,503	$	30,421		$	—		$	797,924
Depreciation and amortization		17,945		1,164			462		$	19,571		26,923		1,818			689		$	29,430
Operating income (loss)		96,660		(418	)		(23,821	)	$	72,421		129,788		(1,392	)		(35,271	)	$	93,125

2023

Automotive and Medical segment product revenues by product category for the three and ~~six~~nine months ended ~~June~~September 30, 2022 and 2021 were as follows:


	Three Months Ended June 30,				Six Months Ended June 30,				Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021		2022		2021		2022		2021
Climate Control Seat	$	96,488	$	98,229	$	199,222	$	207,402	$	112,059	$	89,991	$	311,281	$	297,393
Seat Heaters		65,903		69,864		134,799		146,585		75,568		61,516		210,367		208,101
Steering Wheel Heaters		28,951		26,697		57,687		55,561		31,482		24,578		89,169		80,139
Automotive Cables		19,280		22,940		41,325		47,221		18,338		19,465		59,662		66,686
Battery Performance Solutions		17,451		17,577		35,064		35,337		20,331		16,928		55,395		52,265
Electronics		10,278		14,652		21,106		29,757		12,083		11,567		33,190		41,324
Lumbar and Massage Comfort Solutions (a)										22,740		—		22,740		—
Valve System Technologies (a)										18,542		—		18,542		—
Other Automotive		10,801		5,146		17,813		12,612		11,412		8,983		29,224		21,595
Subtotal Automotive segment		249,152		255,105		507,016		534,475		322,555		233,028		829,570		767,503
Medical segment		11,563		10,900		21,356		20,065
Medical segment (a)										10,407		10,356		31,764		30,421
Total Company	$	260,715	$	266,005	$	528,372	$	554,540	$	332,962	$	243,384	$	861,334	$	797,924

(a)

Includes product revenues from acquisitions since their respective acquisition dates (see Note 3).

Total product revenues information by geographic area for the three and ~~six~~nine months ended ~~June~~September 30, 2022 and 2021 is as follows (based on shipment destination):


	Three Months Ended June 30,				Six Months Ended June 30,				Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021		2022		2021		2022		2021
United States	$	102,617	$	102,174	$	206,738	$	217,461	$	131,021	$	96,683	$	337,759	$	314,144
China		31,391		33,857		69,744		67,372		57,439		32,198		127,183		99,570
South Korea		23,706		25,516		44,881		50,156		22,751		20,894		67,632		71,050
Germany		15,565		16,350		35,351		35,530		19,454		16,011		54,805		51,541
Japan										17,603		17,054		42,305		52,607
Romania		11,519		14,866		24,273		29,951		11,592		10,850		35,866		40,801
Japan		12,886		17,633		24,702		35,553
Czech Republic										13,247		7,650		35,630		33,460
Finland										9,757		7,866		26,244		21,780
Slovakia										8,109		6,294		25,755		23,655
Canada										5,093		4,704		17,047		14,403
Other		63,032		55,609		122,682		118,517		36,896		23,180		91,108		74,913
Total Non-U.S.		158,098		163,831		321,634		337,079		201,941		146,701		523,575		483,780
Total Company	$	260,715	$	266,005	$	528,372	$	554,540	$	332,962	$	243,384	$	861,334	$	797,924

2124

~~Note 15 – Subsequent Events~~

On May 4, 2022, the Company entered into a definitive purchase agreement to acquire the automotive business of Alfmeier Präzision SE (“Alfmeier”), a global leader in automotive lumbar and massage comfort solutions and a leading provider of advanced valve systems technology, integrated electronics and software. Also on May 4, 2022, the Company entered into a put and call option agreement with one of the owners of Alfmeier for the real property in Germany on which Alfmeier’s headquarters is located. Pursuant to this agreement, the seller had a put to sell the headquarters to the Company and the Company had an option to purchase the headquarters post-closing of the acquisition of Alfmeier. Prior to the closing of the acquisition, Alfmeier and certain of its subsidiaries completed a series of carve-out transactions such that Alfmeier’s industrial and non-automotive business would not be acquired by the Company. On July 29, 2022, the Company completed the acquisition of Alfmeier through the acquisition of all shares in Alfmeier for a total purchase price of €~~181,500~~ ~~(approximately $184,871~~ at foreign exchange rates as of such date), net of cash and cash-like items and debt and debt-like items, and subject to customary adjustments related to Alfmeier’s net working capital as of the closing. The Alfmeier purchase price was increased by €~~4,000~~ ~~(approximately $4,074~~ at foreign exchange rates as of such date) at closing as a result of the resolution of certain Alfmeier tax matters prior to closing. Also, on July 29, 2022, the Company completed the acquisition of Alfmeier’s headquarters for a purchase price of €~~10,500~~ ~~(approximately $10,730~~ ~~at foreign exchange rates as of such date). The transactions were funded through a combination of the Company’s existing cash balances and borrowings under the Revolving Credit Facility.~~

On July 13, 2022, the Company completed the acquisition of Jiangmen Dacheng Medical Equipment Co. Ltd (“Dacheng”) and its wholly owned subsidiary, IOB Medical, Inc. (“IOB”). Dacheng, a privately held company headquartered in Jiangmen, Guangdong Province, China, is a manufacturer of medical materials and medical equipment, including patient temperature management solutions, for numerous local and international customers. The acquisition provides Gentherm Medical a local presence in China’s high-growth market for patient warming devices and other medical device products, while also expanding overall manufacturing capacity to include a low-cost manufacturing site. The Company acquired all shares in Dacheng for $~~34,300, net of cash and debt, and subject to customary adjustments related to Dacheng’s net working capital as of the closing. The purchase price may be increased by up to $3,000~~ ~~post-closing upon the achievement of certain milestones. Also, as part of the transaction but not the purchase price or net working capital, IOB retained the obligation to satisfy an existing $2,700~~ ~~consulting fee for work performed on IOB’s behalf. The transaction was funded through a combination of the Company’s existing cash balances and borrowings under the Revolving Credit Facility.~~

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-Looking Statements

This Quarterly Report on Form 10-Q (this “Report”) contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent our goals, beliefs, plans and expectations about our prospects for the future and other future events, such as the impact of the COVID-19 pandemic on our financial statements, liquidity, and business as well as the global economy, global supply chain and automotive and medical industries, the impact of sustained price increases for various material components and shipping costs, the impact of the conflict in Ukraine on our operations, the expected synergies and growth prospects following the closing of recent acquisitions, the significant supply disruptions and shifts in the labor market currently faced by the automotive and medical industries, our ability and our customers’ ability to maintain production levels, the amount of borrowing availability under the Second Amended and Restated Credit Agreement and the sufficiency of our cash balances and cash generated from operating, investing and financing activities for our future liquidity and capital resource needs and our ability to finance sufficient working capital. Reference is made in particular to forward-looking statements included in this “Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations”. Such statements may be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “believe”, “estimate”, “anticipate”, “intend”, “continue”, or similar terms, variations of such terms or the negative of such terms. The forward-looking statements included in this Report are made as of the date hereof or as of the date specified herein and are based on management’s current expectations and beliefs. Such statements are subject to a number of assumptions, risks, uncertainties and other factors, which are set forth in “Item 1A. Risk Factors” and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2021, as amended by Part II “Item 1A. Risk Factors” in our ~~Current~~Quarterly Report on Form 10-Q for the three months ended March 31, 2022 and subsequent reports filed with the Securities and Exchange Commission, and which could cause actual results to differ materially from that described in the forward-looking statements. In addition, except for the recently consummated acquisitions, such forward-looking statements do not include the potential impact of any other business combinations, acquisitions, divestitures, strategic investments and other significant transactions that may be completed after the date hereof, each of which may present material risks to the Company’s business and financial results. Except as required by law, we expressly disclaim any obligation or undertaking to update any forward-looking statements to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

The following discussion and analysis should be read in conjunction with, and is qualified in its entirety by, our consolidated condensed financial statements and related notes thereto included elsewhere in this Report and our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2021.

Overview

Gentherm Incorporated is athe global ~~developer, manufacturer and marketer~~market leader of innovative thermal management ~~technologies for a broad range of heating, cooling and temperature control applications, primarily for the automotive and medical industries~~ and pneumatic comfort technologies for the automotive industry. ~~Within the~~Automotive products include variable temperature Climate Control Seats, heated automotive ~~industry, our products provide~~interior systems (including heated seats, steering wheels, armrests and other components), battery performance solutions, ~~for passenger climate comfort and convenience,~~cable systems, lumbar and massage comfort solutions, valve system technologies, ~~battery thermal management~~ and ~~cell connecting systems. Within the medical industry our~~other electronic devices. Medical products ~~provide~~include patient temperature management ~~solutions.~~systems. The Company is also developing a number of new technologies and products that will help enable improvements to existing products and to create new product applications for existing and new markets. Our automotive products can be found on vehicles manufactured by nearly all the major OEMs operating in North America and Europe, and several major OEMs in Asia. We operate in locations aligned with our major customers’ product strategies to provide locally enhanced design, integration and production capabilities. The Company is also developing a number of new technologies and products that are expected to enable improvements to existing products and to create new product applications for existing and new markets.

2325

Our sales are driven by the number of vehicles produced by the OEMs, which is ultimately dependent on consumer demand for automotive vehicles, our product content per vehicle, and other factors that may limit or otherwise impact production by us, our supply chain and our customers. Historically, new vehicle demand and product content (i.e. vehicle features) have been driven by macro-economic and other factors, such as interest rates, automotive manufacturer and dealer sales incentives, fuel prices, consumer confidence, employment levels, income growth trends and government and tax incentives. Vehicle content has also been driven by trends in consumer preferences, such as preferences for smart devices and features, personalized user experience, and comfort, health and wellness. Economic volatility or weakness, as well as geopolitical factors, in North America, Europe or Asia, have had and could result in a significant reduction in automotive sales and production by our customers, which have and would have an adverse effect on our business, results of operations and financial condition. In 2020 and 2021, and continuing into 2022, the automotive industry has experienced fluctuating demand and production disruptions related to supply chain challenges, facility closures, labor shortages, work stoppages and inflationary pressures, as ~~a result of the COVID-19 pandemic and associated macroeconomic conditions, as~~ described below. We believe our diversified OEM customer base and geographic revenue base, along with our flexible cost structure, have well positioned us to withstand the impact of industry downturns ~~including the ongoing impact of the COVID-19 pandemic and associated economic conditions,~~ and benefit from industry upturns in the ordinary course. However, shifts in the mix of global automotive production to higher cost regions or to vehicles with less of our product content as well as continuing production challenges and inflationary pressures could adversely impact our profitability. In addition, we may be adversely impacted by volatility, weakness or accelerated growth in markets for hybrid or electric vehicles specifically. We believe our products offer certain advantages for hybrid and electric vehicles, including improved energy efficiency, and position us well to withstand changes in the volume mix between vehicles driven by internal combustion engines and hybrid and other electric vehicles. We also believe that products we are developing, such as ClimateSense®, and our acquisition of Alfmeier’s pneumatic comfort solutions, position us well to address trends in consumer preferences such as personalized user experience, comfort, health and wellness.

Recent Trends

General Economic Conditions

The COVID-19 pandemic that began around December 2019 introduced significant volatility to the global economy, disrupted supply chains and had a widespread adverse effect on the global automotive industry in the first half of 2020, with various direct and indirect adverse impacts continuing throughout 2021 and into 2022.

Beginning in February 2020 and continuing into June 2020, substantially all of the Company’s major OEM and Tier 1 customers temporarily ceased or significantly reduced production as a result of restrictions that were requested or mandated by governmental authorities. As a result, substantially all of our manufacturing facilities either temporarily suspended production or experienced significant reductions in volumes during this period. By the end of the second quarter of 2020, the Company had reopened all of its manufacturing facilities, in line with industry demand, and in accordance with local government requirements. Although global automotive industry production has improved relative to the first half of 2020, production remains below recent historic levels.

The lingering impacts of COVID-19 throughout 2021 and into 2022 have impeded global supply chains, resulted in longer lead times and delays in procuring component parts and raw materials, and resulted in inflationary cost increases in certain raw materials, labor and transportation. These broad-based inflationary impacts have negatively impacted the Company’s financial condition, results of operations and cash flows throughout 2021 and into 2022. We expect these inflationary impacts to continue for the foreseeable future.

Supply shortages of semiconductor chips and other components have resulted in decreases in global automotive vehicle production and significant volatility in customer vehicle production schedules. The Company's semiconductor suppliers, along with most automotive component supply companies that use semiconductors, including Gentherm, have been unable to fully meet the vehicle production demands of the OEMs due to events which are outside the Company's control, including but not limited to, the COVID-19 pandemic, the global semiconductor shortage, fires at suppliers’ facilities, significant weather events impacting semiconductor supplier facilities in the southern United States, and other extraordinary events. The Company was able to mitigate the impacts of supply chain disruptions in order to satisfy customer orders during the first three quarters of 2021; however, during the fourth quarter of 2021 and continuing into 2022 we have experienced and may continue to experience direct adverse impacts of ongoing shortages of semiconductors. Our ability to meet customer orders without significant delay and/or expense for the remainder of 2022 and beyond remains subject to significant uncertainty.

2426

In response to the global supply chain instability and inflationary cost increases the Company has taken several actions to minimize any potential and actual adverse impacts by working closely with its suppliers and customers to closely monitor the availability of semiconductor microchips and other component parts and raw materials, customer vehicle production schedules and any other supply chain inefficiencies that may arise. We expect global supply chain instability will continue to have an adverse impact on our business and financial performance for the foreseeable future, and such adverse impact may be material. The consequences of the pandemic, global supply chain instability and inflationary cost increases and their adverse impact to the global economy continue to evolve. Accordingly, the significance of the future adverse impact on our business and financial statements remains subject to significant uncertainty as of the date of this filing.

In addition to the direct and indirect impacts of COVID-19, the United States and global markets are experiencing volatility and disruption following the escalation of geopolitical tensions and the military conflict between Russia and Ukraine. In February 2022, Russia launched a full-scale military invasion of Ukraine. As a result of the conflict, the United States, United Kingdom, European Union and other countries have levied economic sanctions and bans on Russia and Russia has responded with its own retaliatory measures. These measures have impacted the ~~availability and~~ price of certain raw materials and energy and could have a lasting impact on regional and global economies.

Our facility in Vynohradiv is on the far western corner of Ukraine near the Hungary border. In 2021, products manufactured at our Ukraine facility represented approximately 11% of the Company’s total revenue, including automotive cables, seat heaters and steering wheel heaters. At this time, our Ukraine facility is operating ~~at normal levels~~ and we ~~have begun~~are in process of executing contingency plans and, in coordination with certain customers, specific equipment and production relocations leveraging our flexible global manufacturing footprint. Our response to the escalating situation is based on a severity level contingency response plan that has been developed with certain customers. As the situation in Ukraine is very fluid, we continue to monitor its effects on our business and we continue to work closely with our customers to adjust our contingency response as necessary.

Acquisitions

On ~~May 4,~~July 29, 2022, the Company ~~entered into a definitive purchase agreement~~transferred consideration to acquire 100% of the ~~automotive business~~equity interests of Alfmeier Präzision SE (“Alfmeier”), a global leader in automotive lumbar and massage comfort solutions and a leading provider of advanced valve systems technology, integrated electronics and software. ~~Also on May 4, 2022,~~The acquisition further expands the Company's current value proposition beyond thermal in comfort, health, wellness, and energy efficiency and aligns well with global consumer demand for expanded offerings in vehicle passenger comfort. The total consideration for this acquisition was $164.9 million. On the closing date, the Company ~~entered into a put and call option agreement with one~~made cash payments of the owners of Alfmeier for the real property in Germany on which Alfmeier’s headquarters is located. Pursuant to this agreement, the seller had a put to sell the headquarters to the Company and the Company had an option to purchase the headquarters post-closing of the acquisition of Alfmeier. Prior to the closing of the acquisition, Alfmeier and certain of its subsidiaries completed a series of carve-out transactions such that Alfmeier’s industrial and non-automotive business would not be acquired by the Company. On July 29, 2022, the Company completed the acquisition of Alfmeier through the acquisition of all shares in Alfmeier for a total purchase price of €181.5approximately $188.9 million, ~~(approximately $184.9 million at foreign exchange rates as of such date),~~ net of cash acquired. We expect to receive cash from the seller of $24.1 million (“Purchase Consideration Receivable”) in connection with the finalization and settlement of post-closing adjustments in accordance with the purchase agreement. Substantially all of the adjustments known as of this filing relate to lower cash on hand as of the closing date than estimated and a pre-closing reorganization transaction. We expect additional adjustments for actual working capital, cash and cash-like items ~~on one hand,~~ and debt and debt-like items ~~on the other hand, and subject to customary adjustments related to Alfmeier’s net working capital~~ as of the ~~closing.~~closing date. All post-closing adjustments are expected to be finalized within 120 days of the closing date, provided there are no disputes. Potential disputes shall be resolved in accordance with the purchase agreement. The ~~Alfmeier purchase price was increased by €4.0 million (approximately $4.1 million at foreign exchange rates~~Purchase Consideration Receivable is recorded in Other current assets in the consolidated condensed balance sheets as of such date) at closing as a result of the resolution of certain Alfmeier tax matters prior to closing. Also, on July 29, 2022, the Company completed the acquisition of Alfmeier’s headquarters for a purchase price of €10.5 million (approximately $10.7 million at foreign exchange rates as of such date). The transactions were funded through a combination of the Company’s existing cash balances and borrowings under the Revolving Credit Facility.September 30, 2022.

On July 13, 2022, the Company completed the acquisition of Jiangmen Dacheng Medical Equipment Co. Ltd (“Dacheng”) and its wholly owned subsidiary, IOB Medical, Inc. (“IOB”). Dacheng, a privately held ~~company headquartered in Jiangmen, Guangdong Province, China, is a~~ manufacturer of medical materials and medical equipment, including patient temperature management solutions, for numerous local and international customers. The acquisition provides Gentherm Medical a local presence in China’s high-growth market for patient warming devices and other medical device products, while also expanding overall manufacturing capacity to include a low-cost manufacturing site. The ~~Company acquired all shares in Dacheng~~total consideration for ~~$34.3~~this acquisition was $35.0 million, which is comprised of cash payments, net of cash ~~and debt, and subject to customary adjustments related to Dacheng’s net working capital as of the closing.~~acquired. The purchase ~~price may be increased by~~agreement also includes future cash payments of up to $3.0 million, ~~post-closing~~contingent upon the achievement of certain ~~milestones. Also, as part~~performance metrics and continued employment of the transaction but not the purchase price or net working capital, IOB retained the obligation to satisfy an existing $2.7 million consulting fee for work performed on IOB’s behalf. The transaction was fundedformer majority shareholder through a ~~combination~~series of defined dates. These contingent payments will be accounted for as compensation expense and will be recorded as a component of selling, general and administrative.

See Note 3, “Acquisitions” of the ~~Company’s existing cash balances and borrowings under the Revolving Credit Facility.~~consolidated condensed financial statements included in this Report for additional information.

2527

Light Vehicle Production Volumes

Our sales are driven by the number of vehicles produced by the automotive manufacturers, which is ultimately dependent on consumer demand for automotive vehicles, and our content per vehicle, and other factors that may limit or otherwise impact production by us, our supply chain and our customers. According to the forecasting firm ~~IHS Markit (July~~S&P Global Mobility (October 2022 release), actual light vehicle production in the three and ~~six~~nine months ended ~~June~~September 30, 2022 in the Company’s key markets of North America, Europe, China, Japan and Korea, as compared to the three and ~~six~~nine months ended ~~June~~September 30, 2021, are shown below (in millions of units):


	Three Months Ended June 30,							Six Months Ended June 30,							Three Months Ended September 30,							Nine Months Ended September 30,
	2022		2021		% Change			2022		2021		% Change			2022		2021		% Change			2022		2021		% Change
North America		3.6		3.2		12.5	%		7.1		6.8		4.4	%		3.7		3.0		24.2	%		10.8		9.8		10.6	%
Europe		3.9		4.1		(4.9	)%		7.9		8.9		(11.2	)%		3.6		3.0		20.3	%		11.5		11.9		(3.3	)%
Greater China		5.5		5.8		(5.2	)%		11.7		11.6		0.9	%		7.2		5.5		31.2	%		19.0		17.2		10.9	%
Japan / South Korea		2.5		2.8		(10.7	)%		5.2		5.8		(10.3	)%		2.8		2.3		22.0	%		8.0		8.1		(0.8	)%
Total light vehicle production volume in key markets		15.5		15.9		(2.6	)%		31.9		33.1		(3.7	)%		17.3		13.7		25.8	%		49.3		46.9		5.1	%

The ~~IHS Markit (July~~S&P Global Mobility (October 2022 release) forecasted light vehicle production volume in the Company’s key markets for full year 2022 to increase to ~~67.2~~67.6 million units, a ~~3.9%~~4.5% increase from full year 2021 light vehicle production volumes. Forecasted light vehicle production volumes are a component of the data we use in forecasting future business. However, these forecasts generally are updated monthly, and future forecasts may be significantly different from period to period due to changes in macroeconomic conditions or matters specific to the automotive industry, such as the fluctuations that occurred in 2020 and remain ongoing due to the direct and indirect impacts of the COVID-19 pandemic. Further, due to differences in regional product mix at our manufacturing facilities, as well as material production schedules from our customers for our products on specific vehicle programs, our future forecasted results do not directly correlate with the global and/or regional light vehicle production forecasts of ~~IHS Markit~~S&P Global Mobility or other third-party sources.

New Business Awards

We believe that innovation is an important element to gaining market acceptance of our products and strengthening our market position. During the ~~second~~third quarter of 2022, we secured new automotive business awards totaling ~~$600.0~~$430 million in the ~~quarter including $190.0 million secured by Alfmeier Präzision SE prior to acquisition closing.~~quarter. Automotive new business awards represent the aggregate projected lifetime revenue of new awards provided by our customers to Gentherm in the applicable period, with the value based on the price and volume projections received from each customer as of the award date. Although automotive new business awards are not firm customer orders, we believe that new business awards are an indicator of future revenue. New business awards are not projections of revenue or future business as of ~~June~~September 30, 2022, the date of this Report or any other date. Customer projections regularly change over time and we do not update our calculation of any new business award after the date initially communicated. Automotive new business awards in the ~~second~~third quarter 2022 also do not reflect, in particular, the impact of the COVID-19 pandemic and related macroeconomic challenges on future business. Revenues resulting from automotive new business awards also are subject to additional risks and uncertainties that are included in this Report or incorporated by reference in “Forward-Looking Statements” above.

Stock Repurchase Program

On December 11, 2020, the Board of Directors authorized a new stock repurchase program (the “2020 Stock Repurchase Program”) to commence upon expiration of the prior stock repurchase program on December 15, 2020. Under the 2020 Stock Repurchase Program, the Company is authorized to repurchase up to $150.0 million of its issued and outstanding Common Stock over a three-year period, expiring December 15, 2023. Repurchases under the 2020 Stock Repurchase Program may be made, from time to time, in amounts and at prices the Company deems appropriate, subject to market conditions, applicable legal requirements, debt covenants and other considerations. During the ~~six~~nine months ended ~~June~~September 30, 2022, we did not make any repurchases under the 2020 Stock Repurchase Program and have a remaining repurchase authorization of $130.0 million as of ~~June~~September 30, 2022.

2628

Reportable Segments

The Company has two reportable segments for financial reporting purposes: Automotive and Medical.

See Note ~~14,~~15, “Segment Reporting”, to the consolidated condensed financial statements included in this Report for a description of our reportable segments as well as their proportional contribution to the Company’s reported product revenues and operating ~~income.~~income (loss). The financial information used by our chief operating decision maker to assess operating performance and allocate resources is based on these reportable segments.

Consolidated Results of Operations

The results of operations for the three and ~~six~~nine months ended ~~June~~September 30, 2022 and 2021, in thousands, were as follows:


	Three Months Ended June 30,									Six Months Ended June 30,									Three Months Ended September 30,									Nine Months Ended September 30,
	2022			2021			Favorable / (Unfavorable)			2022			2021			Favorable / (Unfavorable)			2022			2021			Favorable / (Unfavorable)			2022			2021			Favorable / (Unfavorable)
Product revenues	$	260,715		$	266,005		$	(5,290	)	$	528,372		$	554,540		$	(26,168	)	$	332,962		$	243,384		$	89,578		$	861,334		$	797,924		$	63,410
Cost of sales		201,338			186,792			(14,546	)		404,882			387,658			(17,224	)		252,610			173,997			(78,613	)		657,492			561,655			(95,837	)
Gross margin		59,377			79,213			(19,836	)		123,490			166,882			(43,392	)		80,352			69,387			10,965			203,842			236,269			(32,427	)
Operating expenses:
Net research and development expenses		19,325			18,227			(1,098	)		39,759			35,830			(3,929	)		22,666			20,590			(2,076	)		62,425			56,420			(6,005	)
Selling, general and administrative expenses		31,943			27,223			(4,720	)		61,251			55,749			(5,502	)		34,859			27,344			(7,515	)		96,109			83,093			(13,016	)
Restructuring expenses		374			2,091			1,717			555			2,882			2,327			6			749			743			561			3,631			3,070
Total operating expenses		51,642			47,541			(4,101	)		101,565			94,461			(7,104	)		57,531			48,683			(8,848	)		159,095			143,144			(15,951	)
Operating income		7,735			31,672			(23,937	)		21,925			72,421			(50,496	)		22,821			20,704			2,117			44,747			93,125			(48,378	)
Interest expense, net		(1,430	)		(630	)		(800	)		(1,999	)		(1,669	)		(330	)
Foreign currency gain (loss)		4,552			(515	)		5,067			6,769			258			6,511
Interest income (expense), net																				714			(515	)		1,229			(1,285	)		(2,184	)		899
Foreign currency (loss) gain																				(8,285	)		133			(8,418	)		(1,516	)		391			(1,907	)
Other income		134			12			122			338			3			335			361			10			351			698			13			685
Earnings before income tax		10,991			30,539			(19,548	)		27,033			71,013			(43,980	)		15,611			20,332			(4,721	)		42,644			91,345			(48,701	)
Income tax expense		3,919			5,748			1,829			8,214			13,313			5,099			5,784			4,646			(1,138	)		13,998			17,959			3,961
Net income	$	7,072		$	24,791		$	(17,719	)	$	18,819		$	57,700		$	(38,881	)	$	9,827		$	15,686		$	(5,859	)	$	28,646		$	73,386		$	(44,740	)

Product revenues by product category, in thousands, for the three and ~~six~~nine months ended ~~June~~September 30, 2022 and 2021, were as follows:


	Three Months Ended June 30,										Six Months Ended June 30,										Three Months Ended September 30,										Nine Months Ended September 30,
	2022		2021		% Change			$ Change			2022		2021		% Change			$ Change			2022		2021		% Change			$ Change			2022		2021		% Change			$ Change
Climate Control Seat	$	96,488	$	98,229		(1.8	)%	$	(1,741	)	$	199,222	$	207,402		(3.9	)%	$	(8,180	)	$	112,059	$	89,991		24.5	%	$	22,068		$	311,281	$	297,393		4.7	%	$	13,888
Seat Heaters		65,903		69,864		(5.7	)%	$	(3,961	)		134,799		146,585		(8.0	)%	$	(11,786	)		75,568		61,516		22.8	%		14,052			210,367		208,101		1.1	%		2,266
Steering Wheel Heaters		28,951		26,697		8.4	%	$	2,254			57,687		55,561		3.8	%	$	2,126			31,482		24,578		28.1	%		6,904			89,169		80,139		11.3	%		9,030
Automotive Cables		19,280		22,940		(16.0	)%	$	(3,660	)		41,325		47,221		(12.5	)%	$	(5,896	)		18,338		19,465		(5.8	)%		(1,127	)		59,662		66,686		(10.5	)%		(7,024	)
Battery Performance Solutions		17,451		17,577		(0.7	)%	$	(126	)		35,064		35,337		(0.8	)%	$	(273	)		20,331		16,928		20.1	%		3,403			55,395		52,265		6.0	%		3,130
Electronics		10,278		14,652		(29.9	)%	$	(4,374	)		21,106		29,757		(29.1	)%	$	(8,651	)		12,083		11,567		4.5	%		516			33,190		41,324		(19.7	)%		(8,134	)
Lumbar and Massage Comfort Solutions (a)																						22,740		—		100.0	%		22,740			22,740		—		100.0	%		22,740
Valve System Technologies (a)																						18,542		—		100.0	%		18,542			18,542		—		100.0	%		18,542
Other Automotive		10,801		5,146		109.9	%	$	5,655			17,813		12,612		41.2	%	$	5,201			11,412		8,983		27.0	%		2,429			29,224		21,595		35.3	%		7,629
Subtotal Automotive segment		249,152		255,105		(2.3	)%	$	(5,953	)		507,016		534,475		(5.1	)%	$	(27,459	)		322,555		233,028		38.4	%		89,527			829,570		767,503		8.1	%		62,067
Medical segment		11,563		10,900		6.1	%	$	663			21,356		20,065		6.4	%	$	1,291
Medical segment (a)																						10,407		10,356		0.5	%		51			31,764		30,421		4.4	%		1,343
Total Company	$	260,715	$	266,005		(2.0	)%	$	(5,290	)	$	528,372	$	554,540		(4.7	)%	$	(26,168	)	$	332,962	$	243,384		36.8	%	$	89,578		$	861,334	$	797,924		7.9	%	$	63,410

(a)

Includes product revenues from acquisitions since their respective acquisition dates (see Note 3).

2729

Product Revenues

Below is a summary of our product revenues, in thousands, for the three months ended ~~June~~September 30, 2022 and 2021:

Three Months Ended June 30,

Variance Due To:

2022

2021

Favorable /
(Unfavorable)

Automotive Volume

FX

Pricing/Other

Total

Product revenues

$
260,715

$
266,005

$
(5,290
)

$
4,388

$
(13,569
)

$
3,891

$
(5,290
)


	Three Months Ended September 30,						Variance Due To:
	2022		2021		Favorable / (Unfavorable)		Automotive Volume		FX			Acquisition		Pricing/Other			Total
Product revenues	$	332,962	$	243,384	$	89,578	$	67,998	$	(18,438	)	$	42,515	$	(2,497	)	$	89,578

Product revenues for the three months ended ~~June~~September 30, 2022 ~~decreased 2.0%~~increased 36.8% as compared to the three months ended ~~June~~September 30, 2021. The ~~decrease~~increase in product revenues is related to ~~unfavorable foreign currency impacts, primarily related to the Euro, Chinese Renminbi and Korean Won, partially offset by~~ increased volumes in our Automotive segment. The increase in product revenues included in Variance Due To Pricing/Other is primarily attributable to price increases as a result of initial cost recoveries from customers in our Automotive segment and negotiated lower annual price reductions from customers. Additional increase in product revenues included in Variance Due To Pricing/Other is a result of an increase in product revenue in our Medical segment.

~~Below is a summary of our product revenues, in thousands, for the six months ended June 30, 2022 and 2021:~~

Six Months Ended June 30,

Variance Due To:

2022

2021

Favorable /
(Unfavorable)

Automotive Volume

FX

Pricing/Other

Total

Product revenues

$
528,372

$
554,540

$
(26,168
)

$
(8,582
)

$
(20,170
)

$
2,584

$
(26,168
)

~~Product revenues for the six months ended June 30, 2022 decreased 4.7% as compared to the six months ended June 30, 2021. The decrease in product revenues is primarily related to decreased~~ volumes in our Automotive segment and the inclusion of sales from Alfmeier and Dacheng since the acquisitions. These increases were partially offset by unfavorable foreign currency impacts, primarily related to the Euro, Chinese Renminbi and Korean Won. The ~~increase~~decrease in product revenues included in Variance Due To Pricing/Other is primarily attributable to ~~price increases as a result of initial cost recoveries from customers~~decreases in customer pricing in our Automotive segment and a decrease in product revenues in our legacy Medical business. Automotive customer pricing was impacted by negotiated lower annual price reductions and cost recoveries from customers. ~~Additional~~

Below is a summary of our product revenues, in thousands, for the nine months ended September 30, 2022 and 2021:


	Nine Months Ended September 30,						Variance Due To:
	2022		2021		Favorable / (Unfavorable)		Automotive Volume		FX			Acquisition		Pricing/Other		Total
Product revenues	$	861,334	$	797,924	$	63,410	$	59,416	$	(38,608	)	$	42,515	$	87	$	63,410

Product revenues for the nine months ended September 30, 2022 increased 7.9% as compared to the nine months ended September 30, 2021. The increase in product revenues ~~included~~is primarily related to increased volumes in ~~Variance Due To Pricing/Other is~~our Automotive segment and the inclusion of sales from Alfmeier and Dacheng since the acquisitions. These increases were partially offset by unfavorable foreign currency impacts, primarily related to the Euro, Chinese Renminbi and Korean Won. Automotive customer pricing was flat as a result of ~~an increase in product revenue in our Medical segment.~~negotiated lower annual price reductions and cost recoveries from customers.

Cost of Sales

Below is a summary of our cost of sales and gross margin, in thousands, for the three months ended ~~June~~September 30, 2022 and 2021:


	Three Months Ended June 30,									Variance Due To:															Three Months Ended September 30,									Variance Due To:
	2022			2021			Favorable / (Unfavorable)			Automotive Volume			Operational Performance			FX			Other			Total			2022			2021			Favorable / (Unfavorable)			Automotive Volume			Operational Performance			FX			Acquisitions and Other			Total
Cost of sales	$	201,338		$	186,792		$	(14,546	)	$	(2,727	)	$	(13,472	)	$	7,280		$	(5,627	)	$	(14,546	)	$	252,610		$	173,997		$	(78,613	)	$	(42,162	)	$	(4,237	)	$	11,326		$	(43,540	)	$	(78,613	)
Gross margin	$	59,377		$	79,213		$	(19,836	)	$	1,661		$	(13,472	)	$	(6,289	)	$	(1,736	)	$	(19,836	)	$	80,352		$	69,387		$	10,965		$	25,836		$	(8,553	)	$	(7,112	)	$	794		$	10,965
Gross margin - Percentage of product revenues		22.8	%		29.8	%																				24.1	%		28.5	%

Cost of sales for the three months ended ~~June~~September 30, 2022 increased ~~7.8%~~45.2% as compared to the three months ended ~~June~~September 30, 2021. The increase in cost of sales is due to increased volumes in our Automotive segment, the inclusion of sales from Alfmeier and Dacheng since the acquisitions and inflation associated with wages, higher freight costs and material ~~costs included in the Variance Due To Operational Performance. This increase was~~costs. These increases were partially offset by favorable foreign currency impacts primarily attributable to the Euro and Chinese Renminbi. ~~The increase in cost of sales included in Variance Due To Other above is due to the following items:~~

•

~~$3.2 million of increase due to wage inflation; and~~

•

~~$1.3 million of increase attributable to higher volumes in the Medical segment~~

2830

Below is a summary of our cost of sales and gross margin, in thousands, for the ~~six~~nine months ended ~~June~~September 30, 2022 and 2021:


	Six Months Ended June 30,									Variance Due To:															Nine Months Ended September 30,									Variance Due To:
	2022			2021			Favorable / (Unfavorable)			Automotive Volume			Operational Performance			FX			Other			Total			2022			2021			Favorable / (Unfavorable)			Automotive Volume			Operational Performance			FX			Acquisitions and Other			Total
Cost of sales	$	404,882		$	387,658		$	(17,224	)	$	5,621		$	(25,480	)	$	11,197		$	(8,562	)	$	(17,224	)	$	657,492		$	561,655		$	(95,837	)	$	(36,541	)	$	(30,036	)	$	22,523		$	(51,783	)	$	(95,837	)
Gross margin	$	123,490		$	166,882		$	(43,392	)	$	(2,961	)	$	(25,480	)	$	(8,973	)	$	(5,978	)	$	(43,392	)	$	203,842		$	236,269		$	(32,427	)	$	22,875		$	(34,033	)	$	(16,085	)	$	(5,184	)	$	(32,427	)
Gross margin - Percentage of product revenues		23.4	%		30.1	%																				23.7	%		29.6	%

Cost of sales for the ~~six~~nine months ended ~~June~~September 30, 2022 increased ~~4.4%~~17.1% as compared to the ~~six~~nine months ended ~~June~~September 30, 2021. The increase in cost of sales ~~within~~is due to increased volumes in our Automotive segment, the ~~Variance Due To Operational Performance is primarily related to~~inclusion of sales from Alfmeier and Dacheng since the acquisitions and inflation associated with higher freight costs and material costs. ~~This increase was~~These increases were partially offset by ~~decreased volumes in our Automotive segment and~~ favorable foreign currency impacts primarily attributable to the Euro and Chinese Renminbi. ~~The increase in cost of sales included in Variance Due To Other above is due to the following items:~~

•

~~$6.5 million of increase due to wage inflation;~~

•

~~$2.0 million of increase attributable to higher volumes in the Medical segment; and~~

•

~~$0.7 million of decrease due to lower stock compensation expense.~~

Net Research and Development Expenses

Below is a summary of our net research and development expenses, in thousands, for the three months ended ~~June~~September 30, 2022 and 2021:


	Three Months Ended June 30,									Three Months Ended September 30,
	2022			2021			Favorable / (Unfavorable)			2022			2021			Favorable / (Unfavorable)
Research and development expenses	$	24,334		$	23,013		$	(1,321	)	$	26,841		$	23,883		$	(2,958	)
Reimbursed research and development expenses		(5,009	)		(4,786	)		223			(4,175	)		(3,293	)		882
Net research and development expenses	$	19,325		$	18,227		$	(1,098	)	$	22,666		$	20,590		$	(2,076	)
Percentage of product revenues		7.4	%		6.9	%					6.8	%		8.5	%

Net research and development expenses for the three months ended ~~June~~September 30, 2022 increased ~~6.0%~~10.1% as compared to the three months ended ~~June~~September 30, ~~2021. The~~2021.The increase in net research and development expenses is primarily related to the inclusion of expenses from Alfmeier since the acquisition and increased ~~project-related spending.~~investments in ClimateSense and battery performance solutions, partially offset by favorable foreign currency impacts.

Below is a summary of our net research and development expenses, in thousands, for the ~~six~~nine months ended ~~June~~September 30, 2022 and 2021:


	Six Months Ended June 30,									Nine Months Ended September 30,
	2022			2021			Favorable / (Unfavorable)			2022			2021			Favorable / (Unfavorable)
Research and development expenses	$	48,237		$	45,439		$	(2,798	)	$	75,077		$	69,322		$	(5,755	)
Reimbursed research and development expenses		(8,478	)		(9,609	)		(1,131	)		(12,652	)		(12,902	)		(250	)
Net research and development expenses	$	39,759		$	35,830		$	(3,929	)	$	62,425		$	56,420		$	(6,005	)
Percentage of product revenues		7.5	%		6.5	%					7.2	%		7.1	%

Net research and development expenses for the ~~six~~nine months ended ~~June~~September 30, 2022 increased ~~11.0%~~10.6% as compared to the ~~six~~nine months ended ~~June~~September 30, 2021. The increase in net research and development expenses is primarily related to the inclusion of expenses from Alfmeier since the acquisition and increased ~~project-related spending~~investments in ClimateSense and ~~lower reimbursements for costs to design, develop and purchase tooling pursuant to customer contracts.~~battery performance solutions, partially offset by favorable foreign currency impacts.

2931

Selling, General and Administrative Expenses

Below is a summary of our selling, general and administrative expenses, in thousands, for the three months ended ~~June~~September 30, 2022 and 2021:


	Three Months Ended June 30,									Three Months Ended September 30,
	2022			2021			Favorable / (Unfavorable)			2022			2021			Favorable / (Unfavorable)
Selling, general and administrative expenses	$	31,943		$	27,223		$	(4,720	)	$	34,859		$	27,344		$	(7,515	)
Percentage of product revenues		12.3	%		10.2	%					10.5	%		11.2	%

Selling, general and administrative expenses for the three months ended ~~June~~September 30, 2022 increased ~~17.3%~~27.5% as compared to the three months ended ~~June~~September 30, 2021. The increase in selling, general and administrative expenses is primarily related to the inclusion of expenses from Alfmeier since the acquisition and increases in acquisition related ~~costs.~~costs, partly offset by lower incentive compensation.

Below is a summary of our selling, general and administrative expenses, in thousands, for the ~~six~~nine months ended ~~June~~September 30, 2022 and 2021:


	Six Months Ended June 30,									Nine Months Ended September 30,
	2022			2021			Favorable / (Unfavorable)			2022			2021			Favorable / (Unfavorable)
Selling, general and administrative expenses	$	61,251		$	55,749		$	(5,502	)	$	96,109		$	83,093		$	(13,016	)
Percentage of product revenues		11.6	%		10.1	%					11.2	%		10.4	%

Selling, general and administrative expenses for the ~~six~~nine months ended ~~June~~September 30, 2022 increased ~~9.9%~~15.7% as compared to the ~~six~~nine months ended ~~June~~September 30, 2021. The increase in selling, general and administrative expenses is primarily related to the inclusion of expenses from Alfmeier since the acquisition and increases in acquisition related ~~costs.~~costs, partly offset by lower incentive compensation.

3032

Restructuring Expenses

Restructuring expenses primarily relate to the Manufacturing Footprint Rationalization restructuring program and other discrete restructuring actions focused on the rotation of our manufacturing footprint to lower cost locations and the reduction of global overhead expenses.

Below is a summary of our restructuring expenses, in thousands, for the three months ended ~~June~~September 30, 2022 and 2021:

Three Months Ended June 30,

2022

2021

Favorable /
(Unfavorable)

Restructuring expenses

$
374

$
2,091

$
1,717


	Three Months Ended September 30,
	2022		2021		Favorable / (Unfavorable)
Restructuring expenses	$	6	$	749	$	743

During the three months ended ~~June~~September 30, 2022, the Company recognized expenses of ~~$0 million for employee separation costs and $0.4~~less than $0.1 million for other costs.

During the three months ended ~~June~~September 30, 2021, the Company recognized expenses of ~~$1.5~~$0.1 million for employee separation costs and $0.6 million of ~~accelerated depreciation and~~ other costs.

Below is a summary of our restructuring expenses, in thousands, for the ~~six~~nine months ended ~~June~~September 30, 2022 and 2021:

Six Months Ended June 30,

2022

2021

Favorable /
(Unfavorable)

Restructuring expenses

$
555

$
2,882

$
2,327


	Nine Months Ended September 30,
	2022		2021		Favorable / (Unfavorable)
Restructuring expenses	$	561	$	3,631	$	3,070

During the ~~six~~nine months ended ~~June~~September 30, 2022, the Company recognized expenses of less than $0.1 million for employee separation costs and $0.5 million for other costs.

During the ~~six~~nine months ended ~~June~~September 30, 2021, the Company recognized expenses of ~~$2.0~~$2.7 million for employee separation costs and ~~$0.9~~$0.8 million of accelerated depreciation and other costs.

See Note 3,4, “Restructuring” of the consolidated condensed financial statements included in this Report for additional information.

Interest ~~Expense,~~Income (Expense), net

Below is a summary of our interest ~~expense,~~income (expense), net, in thousands, for the three months ended ~~June~~September 30, 2022 and 2021:

Three Months Ended June 30,

2022

2021

Favorable /
(Unfavorable)

Interest expense, net

$
(1,430
)

$
(630
)

$
(800
)


	Three Months Ended September 30,
	2022		2021			Favorable / (Unfavorable)
Interest income (expense), net	$	714	$	(515	)	$	1,229

Interest ~~expense,~~income (expense), net for the three months ended ~~June~~September 30, 2022 ~~increased 127.0%~~decreased 238.6% as compared to the three months ended ~~June~~September 30, 2021. The ~~increase~~decrease is primarily due to the change in fair value of the interest rate swap derivative during the three months ended ~~June~~September 30, ~~2022.~~2022, partially offset by increased interest from a higher balance on our revolving credit agreement during the three months ended September 30, 2022, as compared to the three months ended September 30, 2021.

Below is a summary of our interest ~~expense,~~income (expense), net, in thousands, for the ~~six~~nine months ended ~~June~~September 30, 2022 and 2021:

Six Months Ended June 30,

2022

2021

Favorable /
(Unfavorable)

Interest expense, net

$
(1,999
)

$
(1,669
)

$
(330
)


	Nine Months Ended September 30,
	2022			2021			Favorable / (Unfavorable)
Interest income (expense), net	$	(1,285	)	$	(2,184	)	$	899

Interest ~~expense,~~income (expense), net for the ~~six~~nine months ended ~~June~~September 30, 2022 ~~increased 19.8%~~decreased 41.2% as compared to the ~~six~~nine months ended ~~June~~September 30, 2021. The ~~increase~~decrease is primarily due to the change in fair value of the interest rate swap derivative during the ~~six~~nine months ended ~~June~~September 30, 2022, partially offset by increased interest from a ~~lower~~higher balance on our revolving credit agreement during the ~~six~~nine months ended ~~June~~September 30, 2022, as compared to the ~~six~~nine months ended ~~June~~September 30, 2021.

3133

Foreign Currency (Loss) Gain ~~(Loss)~~

Below is a summary of our foreign currency gain (loss), in thousands, for the three months ended ~~June~~September 30, 2022 and 2021:

Three Months Ended June 30,

2022

2021

Favorable /
(Unfavorable)

Foreign currency gain (loss)

$
4,552

$
(515
)

$
5,067


	Three Months Ended September 30,
	2022			2021		Favorable / (Unfavorable)
Foreign currency (loss) gain	$	(8,285	)	$	133	$	(8,418	)

Foreign currency (loss) gain for the three months ended ~~June~~September 30, 2022 included net realized foreign currency ~~gain~~loss of ~~$0.5~~$3.0 million and net unrealized foreign currency ~~gain~~loss of ~~$4.0~~$5.3 million.

Foreign currency ~~loss~~(loss) gain for the three months ended ~~June~~September 30, 2021 primarily included net realized foreign currency loss of ~~$0.5 million.~~$0.9 million and net unrealized foreign currency gain of $1.0 million

Below is a summary of our foreign currency gain, in thousands, for the ~~six~~nine months ended ~~June~~September 30, 2022 and 2021:

Six Months Ended June 30,

2022

2021

Favorable /
(Unfavorable)

Foreign currency gain

$
6,769

$
258

$
6,511


	Nine Months Ended September 30,
	2022			2021		Favorable / (Unfavorable)
Foreign currency (loss) gain	$	(1,516	)	$	391	$	(1,907	)

Foreign currency (loss) gain for the ~~six~~nine months ended ~~June~~September 30, 2022 included net realized foreign currency ~~gain~~loss of ~~$0.4~~$2.6 million and net unrealized foreign currency gain of ~~$6.4~~$1.1 million.

Foreign currency (loss) gain for the ~~six~~nine months ended ~~June~~September 30, 2021 primarily included net realized foreign currency loss of $0.9 million and net unrealized foreign currency gain of ~~$0.3~~$1.3 million.

Other Income

Below is a summary of our other income, in thousands, for the three months ended ~~June~~September 30, 2022 and 2021:

Three Months Ended June 30,

2022

2021

Favorable /
(Unfavorable)

Other income

$
134

$
12

$
122


	Three Months Ended September 30,
	2022		2021		Favorable / (Unfavorable)
Other income	$	361	$	10	$	351

The increase in ~~Other~~other income is due to an increase in miscellaneous income.

Below is a summary of our other income, in thousands, for the ~~six~~nine months ended ~~June~~September 30, 2022 and 2021:

Six Months Ended June 30,

2022

2021

Favorable /
(Unfavorable)

Other income

$
338

$
3

$
335


	Nine Months Ended September 30,
	2022		2021		Favorable / (Unfavorable)
Other income	$	698	$	13	$	685

The increase in ~~Other~~other income is due to an increase in miscellaneous income.

Income Tax Expense

Below is a summary of our income tax expense, in thousands, for the three months ended ~~June~~September 30, 2022 and 2021:

Three Months Ended June 30,

2022

2021

Favorable /
(Unfavorable)

Income tax expense

$
3,919

$
5,748

$
1,829


	Three Months Ended September 30,
	2022		2021		Favorable / (Unfavorable)
Income tax expense	$	5,784	$	4,646	$	(1,138	)

Income tax expense was ~~$3.9~~$5.8 million for the three months ended ~~June~~September 30, 2022, on earnings before income tax of ~~$11.0~~$15.6 million, representing an effective tax rate of ~~35.7%~~37.1%. The effective tax rate differed from the U.S. Federal statutory rate of 21.0% primarily due to the impact of income taxes on foreign earnings taxed at rates varying from the U.S. statutory rate, the unfavorable impact of the global intangible low-tax income (“GILTI”), and the ~~increase of accruals~~quarterly accrual for uncertain tax positions, partially offset by the impact of certain favorable tax effects on equity vesting.

3234

Income tax expense was ~~$5.7~~$4.6 million for the three months ended ~~June~~September 30, 2021 on earnings before income tax of ~~$30.5~~$20.3 million representing an effective tax rate of ~~18.8%~~22.9%. The effective tax rate differed from the U.S. Federal statutory rate of ~~21%~~21.0% primarily due to ~~certain favorable~~the unfavorable impact of quarterly accrual for uncertain tax ~~effect on equity vesting~~positions, GILTI, withholding taxes and ~~intercompany transactions in the second quarter of 2021,~~other non-deductible expenses, partially offset by ~~unfavorable~~the impact of ~~GILTI.~~income taxes on foreign earnings taxed at rates varying from the U.S. statutory rate in the third quarter of 2021.

Below is a summary of our income tax expense, in thousands, for the ~~six~~nine months ended ~~June~~September 30, 2022 and 2021:

Six Months Ended June 30,

2022

2021

Favorable /
(Unfavorable)

Income tax expense

$
8,214

$
13,313

$
5,099


	Nine Months Ended September 30,
	2022		2021		Favorable / (Unfavorable)
Income tax expense	$	13,998	$	17,959	$	3,961

Income tax expense was ~~$8.2~~$14.0 million for the ~~six~~nine months ended ~~June~~September 30, 2022, on earnings before income tax of ~~$27.0~~$42.6 million, representing an effective tax rate of ~~30.4%~~32.8%. The effective tax rate differed from the U.S. Federal statutory rate of ~~21%~~21.0% primarily due to the impact of income taxes on foreign earnings taxed at rates varying from the U.S. statutory rate, the unfavorable impact of GILTI, and the ~~increase of accruals~~quarterly accrual for uncertain tax positions, partially offset by the impact of certain favorable tax effects of equity vesting.

Income tax expense was ~~$13.3~~$18.0 million for the ~~six~~nine months ended ~~June~~September 30, 2021 on earnings before income tax of ~~$71.0~~$91.3 million representing an effective tax rate of ~~18.7%~~19.7%. The effective tax rate differed from the U.S. Federal statutory rate of ~~21%~~21.0% primarily due to certain favorable tax effect on equity vesting, ~~and~~ intercompany transactions in 2021 and the impact of income taxes on foreign earnings taxed at rates varying from the U.S. statutory rate, partially offset by the unfavorable impact of ~~GILTI.~~uncertain tax positions, GILTI, withholding taxes and other non-deductible expenses.

Liquidity and Capital Resources

Overview

Our primary sources of liquidity and capital resources are cash flows from operations and borrowings available under our Second Amended and Restated Credit Agreement. Our cash requirements consist principally of working capital, capital expenditures, research and development, operating lease payments, income tax payments and general corporate purposes. We generally reinvest available cash flows from operations into our business, while opportunistically utilizing our authorized stock repurchase program. Further, we continuously evaluate acquisition and investment opportunities that will enhance our business strategies.

As of ~~June~~September 30, 2022, the Company had ~~$157.3~~$139.2 million of cash and cash equivalents, ~~$357.0~~$264.5 million of availability under our Second Amended and Restated Credit Agreement and ~~$32.4~~$38.0 million of availability under our ~~North America~~ receivables factoring ~~arrangement.~~arrangements. Significant changes in liquidity occurred during July 2022 in connection with the close of the Alfmeier and Dacheng acquisitions. See "Material Cash Requirements" below for further information. We continue to maintain access to the capital markets and may issue debt or equity securities, which may provide an additional source of liquidity. There can be no assurance equity or debt financing will be available to us when we need it or, if available, the terms will be satisfactory to us and not dilutive to our then-current shareholders.

We continue to expect to be able to move funds between different countries to manage our global liquidity needs without material adverse tax implications, subject to current monetary policies and the terms of the Second Amended and Restated Credit Agreement. We utilize a combination of strategies, including dividends, cash pooling arrangements, intercompany loan repayments and other distributions and advances to provide the funds necessary to meet our global liquidity needs. There are no significant restrictions on the ability of our subsidiaries to pay dividends or make other distributions to Gentherm Incorporated. As of ~~June~~September 30, 2022, the Company’s cash and cash equivalents held by our non-U.S. subsidiaries totaled approximately ~~$141.1~~$117.8 million. If additional non-U.S. cash was needed for our U.S. operations, we may be required to accrue and pay withholding if we were to distribute such funds from non-U.S. subsidiaries to the U.S.; however, based on our current liquidity needs and strategies, we do not anticipate a need to accrue and pay such additional amounts.

We currently believe that our cash and cash equivalents and borrowings available under our Second Amended and Restated Credit Agreement and ~~the North America~~ receivables factoring ~~arrangement~~arrangements will be adequate to meet anticipated cash requirements for at least the next twelve months and the foreseeable future.

3335

Cash and Cash Flows

The following table represents our cash and cash equivalents, in thousands:


	Six Months Ended June 30,						Nine Months Ended September 30,
	2022			2021			2022			2021
Cash and cash equivalents at beginning of period	$	190,606		$	268,345		$	190,606		$	268,345
Net Cash (used in) provided by operating activities		(3,686	)		84,362
Net Cash provided by operating activities								12,957			117,106
Net Cash used in investing activities		(15,717	)		(25,859	)		(247,841	)		(39,958	)
Net Cash used in financing activities		(5,145	)		(139,625	)
Net Cash provided by (used in) financing activities								191,582			(148,586	)
Foreign currency effect on cash and cash equivalents		(8,800	)		(360	)		(8,141	)		(1,821	)
Cash and cash equivalents at end of period	$	157,258		$	186,863		$	139,163		$	195,086

Cash Flows From Operating Activities

Cash ~~used in~~provided by operating activities totaled ~~$3.7~~$13.0 million during the ~~six~~nine months ended ~~June~~September 30, 2022 primarily reflecting net income of ~~$18.8~~$28.6 million ~~decreased by non-cash adjustments of $1.0 million for deferred income taxes~~ and ~~$46.6 million related to changes in assets and liabilities, partially offset by $25.1~~$35.3 million for non-cash charges for depreciation, amortization, non-cash stock based compensation, loss on disposition of property and equipment and pension plan ~~adjustments.~~adjustments, partially offset by non-cash adjustments of $1.8 million for gains on revaluation of derivatives, $1.2 million for deferred income taxes and $47.9 million related to changes in assets and liabilities.

Cash Flows From Investing Activities

Cash used in investing activities was ~~$15.7~~$247.8 million during the ~~six~~nine months ended ~~June~~September 30, 2022, reflecting payments for the Alfmeier and Dacheng acquisitions of $224.1 million and purchases of property and equipment of ~~$15.4 million and payments related to an equity method investment for $0.4~~$25.7 million, partially offset by proceeds from deferred purchase price of factored receivables of $2.2 million and the sale of property and equipment of ~~$0.1~~$0.2 million.

Cash Flows From Financing Activities

Cash ~~used in~~provided by financing activities was ~~$5.1~~$191.6 million during the ~~six~~nine months ended ~~June~~September 30, 2022, reflecting net borrowings of debt of $195.4 million and proceeds from the exercise of Common Stock options totaling $1.6 million, partially offset by taxes withheld and paid on employees' share based payment awards totaling ~~$4.5 million and repayments of debt of $1.2 million, partially offset by proceeds from the exercise of Common Stock options totaling $0.6~~$5.4 million.

Debt

The following table summarizes the Company’s debt, in thousands, as of ~~June~~September 30, 2022 and 2021:


	June 30, 2022						June 30, 2021						September 30, 2022						September 30, 2021
	Interest Rate			Principal Balance			Interest Rate			Principal Balance			Interest Rate			Principal Balance			Interest Rate			Principal Balance
Credit Agreement:
U.S. Revolving Note (U.S. Dollar denominations)		2.42	%	$	35,000			1.35	%	$	35,000			4.26	%	$	232,000			1.35	%	$	35,000
U.S. Revolving Note (Euro denominations)		—			—			1.25	%		8,294
DEG Vietnam Loan		5.21	%		2,500			5.21	%		5,000
Other loans													3.93% - 5.21%				3,540			5.21	%		5,000
Total debt					37,500						48,294						235,540						40,000
Current maturities					(2,500	)					(2,500	)					(3,540	)					(2,500	)
Long-term debt, less current maturities				$	35,000					$	45,794					$	232,000					$	37,500

3436

Credit Agreement

Gentherm, together with certain of its subsidiaries, maintain a revolving credit note (“U.S. Revolving Note”) under its Second Amended and Restated Credit Agreement (the “Second Amended and Restated Credit Agreement”) with a consortium of lenders and Bank of America, N.A. as administrative agent. The Second Amended and Restated Credit Agreement was entered into on June 10, 2022 and amends and restates in its entirety the Amended and Restated Credit Agreement dated June 27, 2019, by and among Gentherm, certain of its direct and indirect subsidiaries, the lenders party thereto and the Agent. The Second Amended and Restated Credit Agreement has a maximum borrowing capacity of $500 million and matures on June 10, 2027. The Second Amended and Restated Credit Agreement contains covenants, that, among other things, (i) prohibit or limit the ability of the borrowers and any material subsidiary to incur additional indebtedness, create liens, pay dividends, make certain types of investments (including acquisitions), enter into certain types of transactions with affiliates, prepay other indebtedness, sell assets or enter into certain other transactions outside the ordinary course of business, and (ii) require that Gentherm maintain a minimum Consolidated Interest Coverage Ratio and a maximum Consolidated Net Leverage Ratio (based on consolidated EBITDA for the applicable trailing four fiscal quarters) as of the end of any fiscal quarter.

DEG Vietnam Loan

The Company also has a fixed interest rate loan with the German Investment Corporation (“DEG”), a subsidiary of KfW Banking Group, a Germany government-owned development bank. The fixed interest rate senior loan agreement with DEG was used to finance the construction and set up of the Vietnam production facility (“DEG Vietnam Loan”). The DEG Vietnam Loan is subject to semi-annual principal payments that began November, 2017 and will end May, 2023.

Other Sources of Liquidity

The Company is party to a receivable factoring ~~agreement~~agreements with ~~HSBC Bank USA, National Association. Under the receivable factoring agreement,~~unrelated third parties under which we can sell receivables for certain ~~of our North America~~ account debtors, ~~up to $41.3 million,~~ on a revolving basis, subject to outstanding balances and concentration limits. The receivable factoring agreements are transferred in their entirety to the acquiring entities and are accounted for as a sale. Some of the agreements, including those assumed through the acquisition of Alfmeier, have deferred purchase price arrangements. As of ~~June~~September 30, 2022, there were no$20.2 million outstanding receivables transferred under the receivable factoring ~~agreement~~agreements and our availability under the receivables factoring ~~agreement~~agreements was ~~$32.4~~$38.0 million.

Material Cash Requirements

Significant liquidity was required during July 2022 to close the Alfmeier and Dacheng acquisitions. In connection with these acquisitions, we drew $202.0 million from the U.S. Revolving Note and made cash payments totaling approximately ~~$232.6~~$224.1 million, including amounts placed in escrow. Additional cash payments may be required for ~~customary adjustments related to Alfmeier’s net working capital as of the closing and for the~~ contingent payments of up to $3.0 million related to the Dacheng acquisition. See "Acquisitions" above for additional information about the purchase prices associated with these transactions.

The Company continues to enter into agreements with suppliers to reserve the right to purchase certain semiconductor chips over periods of 12-24 months. As of ~~June~~September 30, 2022, the Company’s total commitments for these semiconductor chip agreements was ~~$40.4~~$37.3 million. See Note 7,8, “Commitments and Contingencies” of the consolidated condensed financial statements included in this Report for additional information.

Except as described above, there have been no material changes in our cash requirements since December 31, 2021, the end of fiscal year 2021. See Part II, Item 7 “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2021 for additional information regarding our material cash requirements.

Effects of Inflation

The automotive component supply industry has historically been subject to inflationary pressures with respect to materials and labor. In 2021 and continuing in 2022, macroeconomic effects of the COVID-19 pandemic have resulted in inflationary cost increases in certain materials, labor and transportation. These inflationary cost increases are expected to continue into the foreseeable future as demand remains elevated and supply remains constrained. Although the Company has developed and implemented strategies to mitigate the impact of higher material component costs and transportation costs, these strategies, together with commercial

negotiations with Gentherm's customers and suppliers have not fully offset to date and may not offset our future cost increases. Such inflationary cost increase may increase the cash required to fund our operations by a material amount.

Critical Accounting Policies

The discussion and analysis of our financial condition and results of operations are based upon our consolidated condensed financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. For discussion of our significant accounting policies, see Note 2, “Summary of Significant Accounting Policies,” to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021. There have been no significant changes in our critical accounting policies or critical accounting estimates during the three months ended ~~June~~September 30, 2022. We are not presently aware of any events or circumstances that would require us to update our estimates, assumptions or revise the carrying value of our assets or liabilities. Our estimates may change, however, as new events occur and additional information is obtained. As a result, actual results may differ significantly from our estimates, and any such differences may be material to our financial statements. ~~For information on the impact of recently issued accounting pronouncements, see Note 2, “New Accounting Pronouncements” in the consolidated condensed financial statements included in this Report.~~

Recent Accounting Pronouncements

For information on the impact of recently issued accounting pronouncements, see Note 2, “New Accounting Pronouncements” in the consolidated condensed financial statements included in this Report.

3638

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The Company’s designated hedging relationships are formally documented at the inception of the hedge, and hedges must be highly effective in offsetting changes to future cash flows on hedged transactions both at the inception of a hedge and on an ongoing basis to be designated for hedge accounting treatment. For derivative contracts that can be classified as a cash flow hedge, the effective portion of the change in the fair value of the derivative is recorded to Accumulated other comprehensive loss in the consolidated condensed balance sheets. When the underlying hedge transaction is realized, the gain or loss included in Accumulated other comprehensive loss is recorded in earnings in the consolidated condensed statements of income on the same line as the gain or loss on the hedged item attributable to the hedged risk. The Company records the ineffective portion of foreign currency and copper commodity hedging instruments, if any, to cost of sales, and the ineffective portion of interest rate swaps, if any, to interest expense in the consolidated condensed statements of income. Cash flows associated with derivatives are reported in net cash (used in) provided by operating activities in the Company’s consolidated condensed statements of cash flows.

Information related to the fair values of all derivative instruments in our consolidated condensed balance sheet as of ~~June~~September 30, 2022 is set forth in Note 9,10, “Financial Instruments” in the consolidated condensed financial statements included in this Report.

Interest Rate Sensitivity

The table presents principal cash flows and related weighted average interest rates by expected maturity dates for each of the Company’s debt obligations. The information is presented in U.S. dollar equivalents, which is the Company’s reporting currency. The instruments actual cash flows are denominated in the currency indicated in parentheses.


	Expected Maturity Date																				Expected Maturity Date
	2022			2023			2024		2025		2026		2027			Total			Fair Value		2022		2023		2024		2025		2026		2027			Total			Fair Value
Liabilities
Long-Term Debt:
Variable rate ($USD)	$	—		$	—		$	—	$	—	$	—	$	35,000		$	35,000		$	35,000	$	—	$	—	$	—	$	—	$	—	$	232,000		$	232,000		$	232,000
Variable interest rate as of June 30, 2022														2.42	%		2.42	%
Variable interest rate as of September 30, 2022																																4.26	%		4.26	%
Fixed rate ($USD)	$	1,250		$	1,250		$	—	$	—	$	—	$	—		$	2,500		$	2,490	$	1,271	$	2,269	$	—	$	—	$	—	$	—		$	3,540		$	3,560
Fixed interest rate		5.21	%		5.21	%											5.21	%			3.93% -5.21%		3.93% -5.21%											3.93% -5.21%

Based on the amounts outstanding as of ~~June~~September 30, 2022, a hypothetical 100 basis point change (increase or decrease) in interest rates would impact annual interest expense by ~~$0.4~~$2.3 million.

In connection with the acquisitions of Alfmeier and Dacheng, we drew $202.0 million from the U.S. Revolving Note in July 2022. To hedge the Company's exposure to interest payment fluctuations on a portion of these borrowings, we entered into a floating-to-fixed interest rate swap agreement with a notional amount of $100.0 million.

3739

Exchange Rate Sensitivity

The table below provides information about the Company’s foreign currency forward exchange rate agreements that are sensitive to changes in foreign currency exchange rates. The table presents the notional amounts and weighted average exchange rates by expected (contractual) maturity dates for each type of foreign currency forward exchange agreement. These notional amounts generally are used to calculate the contractual payments to be exchanged under the contract.

During the three months ended June 30, 2022, the Company entered into forward contracts with a notional amount of $128.3 million to hedge the foreign currency risk associated with the expected closing of Alfmeier.

Expected Maturity or Transaction Date

Anticipated Transactions and Related Derivatives

2022

Total

Fair Value

USD Functional Currency

Forward Exchange Agreements:

(Receive $MXN / Pay $USD)

Total contract amount

$
14,075

$
14,075

$
588

Average contract rate

21.31

21.31

(Receive $EUR / Pay $USD)

Total contract amount

$
128,319

$
128,319

$
482

Average contract rate

0.96

0.96


	Expected Maturity or Transaction Date
Anticipated Transactions and Related Derivatives	2022		2023		2024
USD Functional Currency
Forward Exchange Agreements:
(Receive $MXN / Pay $USD)
Total contract amount	$	6,977	$	27,093	$	12,970
Average contract rate		21.50		22.15		23.13

The table below presents the potential gain and loss in fair value for the foreign currency derivative contracts from a hypothetical 10% change in quoted currency exchange rates.

June 30, 2022

December 31, 2021

Exchange Rate Sensitivity

Potential loss in fair value

Potential gain in fair value

Potential loss in fair value

Potential gain in fair value

Forward Exchange Agreement:(Receive $MXN / Pay $USD)

$
1,332

$
1,628

$
1,296

$
1,584

Forward Exchange Agreement:(Receive $EUR / Pay $USD)

$
33,300

$
40,700

$
—

$
—


	September 30, 2022				December 31, 2021
Exchange Rate Sensitivity	Potential loss in fair value		Potential gain in fair value		Potential loss in fair value		Potential gain in fair value
Forward Exchange Agreement:(Receive $MXN / Pay $USD)	$	4,484	$	5,481	$	1,296	$	1,584

The model assumes a parallel shift in currency exchange rates; however, currency exchange rates rarely move in the same direction. The assumption that currency exchange rates change in a parallel fashion may overstate the impact of changing currency exchange rates on assets and liabilities denominated in currencies other than the U.S. dollar.

ITEM 4. CONTROLS AND PROCEDURES

(a) Evaluation of Disclosure Controls and Procedures

Management of the Company, under the supervision and with the participation of the Chief Executive Officer and the Chief Financial Officer, carried out an evaluation of the effectiveness of the design and operation of the Company’s disclosure controls and procedures as of ~~June~~September 30, 2022. As defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (as amended, the “Exchange Act”), disclosure controls and procedures are controls and procedures designed to provide reasonable assurance that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported on a timely basis, and that such information is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based upon this evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that the Company’s disclosure controls and procedures were effective as of ~~June~~September 30, 2022.

(b) Changes in Internal Control over Financial Reporting

~~There~~In conjunction with our recent acquisition activity, we utilized our framework of internal control over financial reporting specific to business combinations. The applicable controls address the various elements of a business combination, including but not limited to: 1) calculation of the consideration transferred; 2) identifying and properly accounting for transactions that are separate from the business combination; 3) use and oversight of competent and qualified personnel in performing the valuation of assets acquired and liabilities assumed; 4) review of inputs and outputs to the valuation models; 5) identifying and disclosing provisional amounts; and 6) tracking measurement period adjustments.

Our acquisition of Dacheng became effective on July 13, 2022 and the acquisition of Alfmeier became effective on July 29, 2022. We are currently integrating policies, processes and operations for the combined companies and will continue to evaluate our internal control over financial reporting as we develop and execute our integration plans. We will exclude the acquired operations of Dacheng and Alfmeier from our assessment of Gentherm’s internal control over financial reporting for the year ended December 31, 2022 as permissible under rules and regulations of the Securities and Exchange Commission.

Except as described above with regard to the acquisition and integration of Alfmeier and Dacheng, there were no changes in ~~the Company’s~~our internal control over financial reporting during the ~~three months~~quarter ended ~~June~~September 30, 2022 that have materially affected, or are reasonably likely to materially affect, ~~the Company’s~~our internal control over financial reporting.

3941

PART II OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We are subject to litigation from time to time in the ordinary course of business, however there is no material pending litigation to which we are a party and no material legal proceeding was terminated, settled or otherwise resolved during the three months ended ~~June~~September 30, 2022.

ITEM 1A. RISK FACTORS

The Company’s risk factors have not materially changed from those previously disclosed in Part 1, Item 1A “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021, as amended by Part II “Item 1A. Risk Factors” in our ~~Current~~Quarterly Report on Form 10-Q for the three months ended March 31, 2022.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Issuer Purchases of Equity Securities During First Quarter 2022

Period

(a)
Total Number
of Shares
Purchased

(b)
Average Price
Paid Per Share

(c)
Total Number of Shares Repurchased as Part of Publicly Announced Plans or Programs

(d)
Approximate Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs (1)

April 1, 2022 to April 30, 2022

—

$
—

—

$
130,000,105

May 1, 2022 to May 31, 2022

—

$
—

—

$
130,000,105

June 1, 2022 to June 30, 2022

—

$
—

—

$
130,000,105


Period	(a) Total Number of Shares Purchased		(b) Average Price Paid Per Share		(c) Total Number of Shares Repurchased as Part of Publicly Announced Plans or Programs		(d) Approximate Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs (1)
July 1, 2022 to July 31, 2022		—	$	—		—	$	130,000,105
August 1, 2022 to August 31, 2022		—	$	—		—	$	130,000,105
September 1, 2022 to September 30, 2022		—	$	—		—	$	130,000,105

(1)

On December 11, 2020, the Board of Directors authorized a new stock repurchase program (the “2020 Stock Repurchase Program”) to commence upon expiration of the prior stock repurchase program on December 15, 2020. Under the 2020 Stock Repurchase Program, the Company is authorized to repurchase up to $150.0 million of its issued and outstanding common stock over a three-year period, expiring December 15, 2023. The authorization of this stock repurchase program does not require that the Company repurchase any specific dollar value or number of shares and may be modified, extended or terminated by the Company’s Board of Directors at any time.

4042

ITEM 6. EXHIBITS

Exhibits to this Report are as follows:

Incorporated by Reference
Exhibit
Number

Exhibit Description

Filed
/Furnished
Herewith

Form

Period
Ending

Exhibit /
Appendix Number

Filing Date
  2.1*

Share Purchase and Transfer Agreement, dated May 4, 2022, by and among Gebhardt Holding GmbH, ELBER GmbH, Gentherm GmbH, and Andreas Gebhardt, Markus Gebhardt and Dr. Johann Vielberth.

10-Q

3/31/22

2.1

5/4/22
  3.1

Second Amended and Restated Articles of Incorporation of Gentherm Incorporated

8-K

3.2

3/5/18
  3.2

Amended and Restated Bylaws of Gentherm Incorporated

8-K

3.1

5/26/16
  10.1*

Second Amended and Restated Credit Agreement, dated as of June 10, 2022, by and among Gentherm Incorporated, Gentherm (Texas), Inc., Gentherm Licensing, Limited Partnership, Gentherm Medical, LLC, Gentherm GmbH, Gentherm Enterprises GmbH and Gentherm Licensing GmbH, the lenders party thereto, and Bank of America, N.A., as administrative agent, swing line lender and L/C issuer.

8-K

10.1

6/13/22
  10.2*

Second Amended and Restated Pledge and Security Agreement, dated as of June 10, 2022, by and among Gentherm Incorporated, Gentherm (Texas), Inc., Gentherm Medical, LLC, Gentherm Properties I, LLC, Gentherm Properties II, LLC and Bank of America, N.A.

8-K

10.2

6/13/22
  31.1

Section 302 Certification – CEO

X

  31.2

Section 302 Certification – CFO

X

  32.1**

Section 906 Certification – CEO

X

  32.2**

Section 906 Certification – CFO

X

101.INS

Inline XBRL Instance Document – The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

X

101.SCH

Inline XBRL Taxonomy Extension Schema Document.

X

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document.

X

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document.

X

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document.

X

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document.

X

104

Cover Page Interactive Data File (embedded within the Inline XBRL document contained in Exhibit 101)

X

Incorporated by Reference

Exhibit

Number

Exhibit Description

Filed

/Furnished

Herewith

Form

Period

Ending

Exhibit /
Appendix Number

Filing Date

3.1

Second Amended and Restated Articles of Incorporation of Gentherm Incorporated

8-K

3.2

3/5/18

3.2

Amended and Restated Bylaws of Gentherm Incorporated

8-K

3.1

5/26/16

31.1

Section 302 Certification – CEO

31.2

Section 302 Certification – CFO

32.1**

Section 906 Certification – CEO

32.2**

Section 906 Certification – CFO

101.INS

Inline XBRL Instance Document – The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

101.SCH

Inline XBRL Taxonomy Extension Schema Document.

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document.

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document contained in Exhibit 101)

* Schedules and exhibits to this agreement have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish any omitted schedules or exhibits upon the request of the SEC. A list of the omitted schedules and exhibits to Exhibit 10.1 is set forth in the agreement. A list of the omitted schedules and exhibits to Exhibit 10.2 is as follows: Schedule I – Pledged Equity Interests; Schedule II – Primary Location, Filing Locations, Trade Names, Changes in Names, State Organizational Numbers, Taxpayer Identification Numbers, Government Contracts, Deposit Accounts, Securities Accounts, Commodity Accounts, Letter of Credit Rights and Commercial Tort Claims; Schedule III – Intellectual Property; Annex I – Security Agreement Supplement.

** Documents are furnished not filed.

4143

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	Gentherm Incorporated

	/s/ PHILLIP EYLER
	Phillip Eyler
	President and Chief Executive Officer
	(Principal Executive Officer)

	Date: ~~August 2,~~November 3, 2022


	/s/ MATTEO ANVERSA
	Matteo Anversa
	Executive Vice President, Chief Financial Officer and Treasurer
	(Principal Financial Officer)

	Date: ~~August 2,~~November 3, 2022

4244


Michigan		95-4318554
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)
21680 Haggerty Road, Northville, MI		48167
(Address of principal executive offices)		(Zip Code)


Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, no par value	THRM	Nasdaq




Part I. Financial Information			3
	Item 1.	Financial Statements (Unaudited)	3
		Consolidated Condensed Balance Sheets	3
		Consolidated Condensed Statements of Income	4
		Consolidated Condensed Statements of Comprehensive (Loss) Income	5
		Consolidated Condensed Statements of Cash Flows	6
		Consolidated Condensed Statements of Changes in Shareholders’ Equity	7
		Notes to Unaudited Consolidated Condensed Financial Statements	8
	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2325
	Item 3.	Quantitative and Qualitative Disclosures About Market Risk	3739
	Item 4.	Controls and Procedures	3941
Part II. Other Information			4042
	Item 1.	Legal Proceedings	4042
	Item 1A.	Risk Factors	4042
	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	4042
	Item 6.	Exhibits	4143
Signatures			4244


	June 30, 2022			December 31, 2021			September 30, 2022			December 31, 2021
ASSETS
Current Assets:
Cash and cash equivalents	$	157,258		$	190,606		$	139,163		$	190,606
Accounts receivable, net		207,364			182,987			248,570			182,987
Inventory:
Raw materials		122,371			96,426			154,273			96,426
Work in process		8,989			9,495			17,157			9,495
Finished goods		56,424			53,556			62,465			53,556
Inventory, net		187,784			159,477			233,895			159,477
Other current assets		40,320			32,775			84,344			32,775
Total current assets		592,726			565,845			705,972			565,845
Property and equipment, net		149,907			155,270			228,056			155,270
Goodwill		62,935			66,033			125,273			66,033
Other intangible assets, net		31,968			37,554			68,639			37,554
Operating lease right-of-use assets		25,924			24,387			30,214			24,387
Deferred income tax assets		67,112			69,630			66,322			69,630
Other non-current assets		16,474			16,624			16,857			16,624
Total assets	$	947,046		$	935,343		$	1,241,333		$	935,343
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current Liabilities:
Accounts payable	$	147,136		$	122,727		$	208,338		$	122,727
Current lease liabilities		5,376			5,669			7,448			5,669
Current maturities of long-term debt		2,500			2,500			3,540			2,500
Other current liabilities		84,206			82,193			100,898			82,193
Total current liabilities		239,218			213,089			320,224			213,089
Long-term debt, less current maturities		35,000			36,250			232,000			36,250
Non-current lease liabilities		18,721			19,789			22,013			19,789
Pension benefit obligation		6,116			6,832			5,850			6,832
Other non-current liabilities		4,796			5,577			37,157			5,577
Total liabilities	$	303,851		$	281,537		$	617,244		$	281,537
Shareholders’ equity:
Common Stock:
No par value; 55,000,000 shares authorized 33,132,691 and 33,008,185 issued and outstanding at June 30, 2022 and December 31, 2021, respectively		121,088			118,646
No par value; 55,000,000 shares authorized 33,196,404 and 33,008,185 issued and outstanding at September 30, 2022 and December 31, 2021, respectively								119,801			118,646
Paid-in capital		5,720			5,866			5,477			5,866
Accumulated other comprehensive loss		(68,648	)		(36,922	)		(96,051	)		(36,922	)
Accumulated earnings		585,035			566,216			594,862			566,216
Total shareholders’ equity		643,195			653,806			624,089			653,806
Total liabilities and shareholders’ equity	$	947,046		$	935,343		$	1,241,333		$	935,343


	Six Months Ended June 30,						Nine Months Ended September 30,
	2022			2021			2022			2021
Operating Activities:
Net income	$	18,819		$	57,700		$	28,646		$	73,386
Adjustments to reconcile net income to net cash (used in) provided by operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		18,635			19,571			30,470			29,430
Deferred income taxes		(997	)		(225	)		(1,207	)		3,867
Non-cash stock based compensation		5,263			7,663			3,383			11,760
Loss on disposition of property and equipment		518			496			620			638
Other		708			(262	)		881			(650	)
Changes in assets and liabilities:
Accounts receivable, net		(31,762	)		11,647			(55,780	)		26,162
Inventory		(33,637	)		(17,211	)		(48,930	)		(34,019	)
Other assets		(10,443	)		8,408			(10,868	)		597
Accounts payable		27,768			(289	)		60,983			9,231
Other liabilities		1,442			(3,136	)		4,759			(3,296	)
Net cash (used in) provided by operating activities		(3,686	)		84,362
Net cash provided by operating activities								12,957			117,106
Investing Activities:
Purchases of property and equipment		(15,448	)		(20,669	)		(25,737	)		(29,585	)
Proceeds from the sale of property and equipment		81			10			175			11
Acquisition of businesses, net of cash acquired								(224,097	)		(2,827	)
Proceeds from deferred purchase price of factored receivables								2,168			—
Cost of technology investments		(350	)		(5,200	)		(350	)		(7,557	)
Net cash used in investing activities		(15,717	)		(25,859	)		(247,841	)		(39,958	)
Financing Activities:
Borrowings on debt								207,000			—
Repayments of debt		(1,250	)		(143,731	)		(11,559	)		(151,993	)
Proceeds from the exercise of Common Stock options		569			6,292			1,556			7,467
Taxes withheld and paid on employees' share-based payment awards		(4,464	)		(2,117	)		(5,415	)		(3,991	)
Acquisition contingent consideration payment		—			(69	)		—			(69	)
Net cash used in financing activities		(5,145	)		(139,625	)
Net cash provided by (used in) financing activities								191,582			(148,586	)
Foreign currency effect		(8,800	)		(360	)		(8,141	)		(1,821	)
Net decrease in cash and cash equivalents		(33,348	)		(81,482	)		(51,443	)		(73,259	)
Cash and cash equivalents at beginning of period		190,606			268,345			190,606			268,345
Cash and cash equivalents at end of period	$	157,258		$	186,863		$	139,163		$	195,086
Supplemental disclosure of cash flow information:
Cash paid for taxes	$	8,642		$	8,563		$	13,509		$	12,348
Cash paid for interest	$	909		$	1,455		$	3,334		$	1,823


Large accelerated filer	☒	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☐
Emerging growth company	☐


									Accumulated																Accumulated
									Other																Other
	Common Stock					Paid-in			Comprehensive			Accumulated					Common Stock					Paid-in			Comprehensive			Accumulated
	Shares		Amount			Capital			Loss			Earnings		Total			Shares		Amount			Capital			Loss			Earnings		Total
Balance at December 31, 2021		33,008	$	118,646		$	5,866		$	(36,922	)	$	566,216	$	653,806			33,008	$	118,646		$	5,866		$	(36,922	)	$	566,216	$	653,806
Net income		—		—			—			—			11,747		11,747			—		—			—			—			11,747		11,747
Other comprehensive loss		—		—			—			(8,806	)		—		(8,806	)		—		—			—			(8,806	)		—		(8,806	)
Stock compensation, net		119		(814	)		(146	)		—			—		(960	)		119		(814	)		(146	)		—			—		(960	)
Balance at March 31, 2022		33,127		117,832			5,720			(45,728	)		577,963		655,787			33,127		117,832			5,720			(45,728	)		577,963		655,787
Net income		—		—			—			—			7,072		7,072			—		—			—			—			7,072		7,072
Other comprehensive loss		—		—			—			(22,920	)		—		(22,920	)		—		—			—			(22,920	)		—		(22,920	)
Stock compensation, net		6		3,256			—			—			—		3,256			6		3,256			—			—			—		3,256
Balance at June 30, 2022		33,133	$	121,088		$	5,720		$	(68,648	)	$	585,035	$	643,195			33,133	$	121,088		$	5,720		$	(68,648	)	$	585,035	$	643,195
Net income																		—		—			—			—			9,827		9,827
Other comprehensive loss																		—		—			—			(27,403	)		—		(27,403	)
Stock compensation, net																		63		(1,287	)		(243	)		—			—		(1,530	)
Balance at September 30, 2022																		33,196	$	119,801		$	5,477		$	(96,051	)	$	594,862	$	624,089


									Accumulated																Accumulated
									Other																Other
	Common Stock					Paid-in			Comprehensive			Accumulated					Common Stock					Paid-in			Comprehensive			Accumulated
	Shares		Amount			Capital			Loss			Earnings		Total			Shares		Amount			Capital			Loss			Earnings		Total
Balance at December 31, 2020		32,921	$	121,073		$	7,458		$	(14,982	)	$	472,782	$	586,331			32,921	$	121,073		$	7,458		$	(14,982	)	$	472,782	$	586,331
Net income		—		—			—			—			32,909		32,909			—		—			—			—			32,909		32,909
Other comprehensive loss		—		—			—			(13,674	)		—		(13,674	)		—		—			—			(13,674	)		—		(13,674	)
Stock compensation, net		190		8,527			(1,335	)		—			—		7,192			190		8,527			(1,335	)		—			—		7,192
Balance at March 31, 2021		33,111		129,600			6,123			(28,656	)		505,691		612,758			33,111		129,600			6,123			(28,656	)		505,691		612,758
Net income		—		—			—			—			24,791		24,791			—		—			—			—			24,791		24,791
Other comprehensive income		—		—			—			4,480			—		4,480			—		—			—			4,480			—		4,480
Stock compensation, net		34		3,142			39			—			—		3,181			34		3,142			39			—			—		3,181
Balance at June 30, 2021		33,145	$	132,742		$	6,162		$	(24,176	)	$	530,482	$	645,210			33,145	$	132,742		$	6,162		$	(24,176	)	$	530,482	$	645,210
Net income																		—		—			—			—			15,686		15,686
Other comprehensive income																		—		—			—			(7,941	)		—		(7,941	)
Stock compensation, net																		80		2,707			(182	)		—			—		2,525
Balance at September 30, 2021																		33,225	$	135,449		$	5,980		$	(32,117	)	$	546,168	$	655,480


	Three Months Ended September 30, 2022			Nine Months Ended September 30, 2022
Product revenues	$	41,281		$	41,281
Operating loss		(3,104	)		(3,104	)



Purchase price, cash consideration, net of cash acquired	$	188,941
Purchase price, Purchase Consideration Receivable	$	(24,054	)
Total purchase price, net of cash acquired	$	164,887

Accounts receivable		24,988
Inventory		36,026
Prepaid expenses and other assets		20,920
Operating lease right-of-use assets		4,608
Property and equipment		89,942
Other intangible assets		22,668
Goodwill		43,678
Assumed liabilities		(55,994	)
Deferred tax liabilities		(21,949	)
Net assets acquired	$	164,887


	Preliminary Fair Value		Weighted Average Life (in years)
Definite-lived:
Customer related	$	11,233		13
Technology		11,435		9
Total	$	22,668



Purchase price, cash consideration, net of cash acquired	$	35,048

Accounts receivable		746
Inventory		1,942
Prepaid expenses and other assets		152
Operating lease right-of-use assets		841
Property and equipment		684
Other intangible assets		19,094
Goodwill		22,995
Assumed liabilities		(2,799	)
Deferred tax liabilities		(8,607	)
Net assets acquired	$	35,048


	Employee Separation Costs			Other Related Costs			Total			Employee Separation Costs			Other Related Costs			Total
Balance at December 31, 2021	$	1,494		$	—		$	1,494		$	1,494		$	—		$	1,494
Additions, charged to restructuring expenses		—			131			131			—			131			131
Cash payments		(544	)		(131	)		(675	)		(544	)		(131	)		(675	)
Non-cash utilization		—			—			—
Change in estimate		50			—			50			50			—			50
Currency translation		(18	)		—			(18	)		(18	)		—			(18	)
Balance at March 31, 2022	$	982		$	—		$	982		$	982		$	—		$	982
Additions, charged to restructuring expenses		—			374			374			—			374			374
Cash payments		(83	)		(97	)		(180	)		(83	)		(97	)		(180	)
Non-cash utilization		—			—			—
Change in estimate		—			—			—
Currency translation		(32	)		—			(32	)		(32	)		—			(32	)
Balance at June 30, 2022	$	867		$	277		$	1,144		$	867		$	277		$	1,144
Additions, charged to restructuring expenses											—			6			6
Cash payments											(248	)		(6	)		(254	)
Currency translation											(31	)		—			(31	)
Balance As of September 30, 2022										$	588		$	277		$	865


	DEG Vietnam Note		U.S. Revolving Note		Total		U.S. Revolving Note		Other Debt		Total
2022	$	1,250	$	—	$	1,250	$	—	$	1,271	$	1,271
2023		1,250		—		1,250		—		2,269		2,269
2024		—		—		—		—		—		—
2025		—		—		—		—		—		—
2026		—		—		—		—		—		—
2027		—		35,000		35,000		232,000		—		232,000
Total	$	2,500	$	35,000	$	37,500	$	232,000	$	3,540	$	235,540


	June 30, 2022							December 31, 2021							September 30, 2022							December 31, 2021
	Gross Carrying Value		Accumulated Amortization			Net Carrying Value		Gross Carrying Value		Accumulated Amortization			Net Carrying Value		Gross Carrying Value		Accumulated Amortization			Net Carrying Value		Gross Carrying Value		Accumulated Amortization			Net Carrying Value
Definite-lived:
Customer relationships	$	82,828	$	(60,761	)	$	22,067	$	90,448	$	(64,105	)	$	26,343	$	99,318	$	(57,718	)	$	41,600	$	90,448	$	(64,105	)	$	26,343
Technology		27,236		(23,411	)		3,825		29,464		(24,487	)		4,977		36,640		(22,502	)		14,138		29,464		(24,487	)		4,977
Product development costs		18,243		(17,844	)		399		20,329		(19,772	)		557		21,250		(16,390	)		4,860		20,329		(19,772	)		557
Software development		1,007		—			1,007		1,007		—			1,007		1,007		—			1,007		1,007		—			1,007
Indefinite-lived:
Tradenames		4,670		—			4,670		4,670		—			4,670		7,034		—			7,034		4,670		—			4,670
Total	$	133,984	$	(102,016	)	$	31,968	$	145,918	$	(108,364	)	$	37,554	$	165,249	$	(96,610	)	$	68,639	$	145,918	$	(108,364	)	$	37,554